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Abstract
Ion channels are macromolecular proteins in cell membranes that control the passage
of charged particles including sodium, potassium and calcium ions in and out of
cells. Rapid electrical signalling in the nervous system is mediated through the
passage of ions through these channels. It is therefore not surprising that genetic
mutations in the genes coding for these channels can result in neurological disease.
Ion channel disorders or channelopathies have emerged in the last ten to fifteen years
as an important new way of understanding neurological disease. Many of these
conditions are paroxysmal in nature and include generalised and focal epilepsies,
movement disorders and neuromuscular disorders. Some of these conditions follow
simple Mendelian inheritance and are rare forms of common disorders such as
epilepsy but they provide a useful model for more common neurological diseases
with complex inheritance. Some conditions such as Dravet syndrome, a severe
infantile onset epilepsy and sodium channelopathy produce devastating
consequences for the affected child.
In this thesis I will describe the clinical work I have undertaken defining phenotypes
of this emerging group of disorders. Detailed phenotyping is the first essential step in
characterising new aspects of these genetic disorders. I have collaborated closely
with molecular geneticists and cell physiologists in units around the world
exchanging ideas in order to better understand the mechanisms of disease and
hopefully translate this into better care for patients. The main themes covered in the
thesis are episodic ataxias type 1 and 2 (EA1 & 2), benign familial neonatal
convulsions, autosomal dominant nocturnal frontal lobe epilepsy, and Dravet
syndrome and other SCN1A related epileptic encephalopathies. In the course of this
work I have described novel relationships between EA1 and EA2 and epilepsy,
described a novel gene and phenotypes associated with frontal lobe epilepsy, a novel
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presentation of a potassium channelopathy, a family with a new genetic mechanism
for their neonatal convulsions and epilepsy, and children with a novel mechanism for
Startle disease (hyperekplexia). I have demonstrated the clinical utility of this
translational research by establishing a molecular genetic diagnostic service for
sodium channel (SCN1A) related infantile epilepsies. A study of the results from this
national UK service shows that genetic diagnosis allows early diagnosis of these
epilepsies. This can result in earlier focused treatment, and the hope for better
epilepsy control and developmental outcome. I discuss the implications of this work
and ongoing and future research projects.
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1.11on Channels in neurological disease
In the last 15 years disorders of ion channel function have emerged as an important
new class of neurological disorder. Ion channels are specialised trans-membrane
proteins that are essential for controlling electrical signalling, the resting membrane
potential of cells and neurotransmitter release throughout the nervous system. The
term channelopathies was coined in 1995 to describe diseases caused by ion channel
dysfunction (Griggs andNutt 1995).
More than 40 genetic neurological channelopathies have been described (Zuberi
2003). The majority of these disorders are single gene syndromes within common
classes of neurological disorders such as epilepsy, movement disorders and migraine.
The study of monogenic channelopathies has resulted in important insights into these
common disorders with complex inheritance, which are the bread and butter of the
neurologist's practice. One of the most exciting aspects ofworking in this field is
seeing how close collaboration between clinicians, molecular geneticists, cell
biologists and physiologists has led to major advances in knowledge which are now
translating back into patient care.
Many of the genetic channelopathies have autoimmune counterparts some ofwhich
are well characterised such as autoimmune myasthenia gravis (acetylcholine receptor
antibodies) and autoimmune neuromyotonia (potassium channel antibodies).
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Recently new autoimmune channelopathies such as potassium (K+) channel antibody
mediated limbic encephalitis have been recognised (Vincent et al 2004).
Many of the advances in the study of the neurological channelopathies have begun
with detailed phenotypic studies of large kindreds which follow monogenic
inheritance (Scheffer & Berkovic, 1997). These families are important as they allow
the study of phenotypic variation among individuals with a shared genetic
background. They also provide the best and most successful approach to molecular
genetic analysis. Large families are more likely to have a single major gene
expressing a neurological disorder than small families where polygenic inheritance is
more likely to occur. By determining the mode of inheritance in a family, assessing
the penetrance of a genetic trait and clearly characterising affected and non-affected
individuals linkage studies can be performed. If there are problems in
characterisation, such as diagnosing just one unaffected member of a family as
affected because they have a similar but unrelated disorder (a phenocopy), then as
detailed in Chapter 8 spurious results can emerge.
Linkage involves defining the regions of chromosomes which are shared among
affected cases and differ from those in the unaffected cases (Pulst 1999). These
studies provide a likelihood, logarithm of the odds score (LOD score), that a known
chromosomal marker is associated with a particular trait. A LOD score of 3 is
generally regarded as significant as it represents 1000:1 odds in favour of linkage.
When a chromosomal region is identified then candidate genes in that part of the
genome can be studied by a variety of techniques including direct sequencing to
search for mutations. If no candidate genes are present or fail to yield positive results
then alternative techniques are used to isolate new genes with mutations.
Many of the channelopathies have had successful genetic characterisation through
this technique. The focus of this thesis is the phenotypic description of
channelopathies that present to the child neurologist. The vast majority of the genetic
channelopathies present in childhood and adolescence. The knowledge of their
genetic basis will allow description of the phenotypic variability within the disorders
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and the boundaries of the disorders. As this is a new field in adult and child
neurology there is great scope for characterisation of the phenotypes which in turn
may aid diagnosis and management of individuals with channelopathies.
It is over 50 years since Hodgkin and Huxley first described the generation of the
nerve action potential in the squid giant axon (Hodgkin & Huxley 1952). They
determined that the electrical impulses were generated by the rapid passage of ions
across the cell membrane through what they termed "active patches". We now call
these patches ion channels and know that they are large macromolecular proteins
which span the cell membrane.
Hodgkin and Huxley developed the patch clamp technique to measure ion movement
as electrical currents (Armstrong & Hille 1998). They were able to mathematically
deduce three of the key properties of ion channels: that they have a central aqueous
pore through which the ions pass, that the pore can be rapidly opened and closed
(gated) and that the channels are selective for different ion species. The advances in
molecular biology of the 1980s which allowed the amino acid sequence of channel
proteins to be described, and the beautiful 3-D pictures of bacterial potassium
channels from X-ray crystallography in the 1990s have all confirmed these properties
(Tempel et all987; Doyle et all999).
Many of the channelopathies are paroxysmal disorders. The ion channel mutation
may impair channel function to a degree that only becomes significant when there
are additional factors which affect channel function. These factors include
temperature, the pH surrounding the channel, intracellular messengers and many
other aspects of the channel micro-environment (Hille 2001). In some disorders
chronic channel dysfunction can result in progressive impairment of function and
interictal signs and symptoms.
The emergence of the channelopathies as a class ofneurological disorder has
benefited from the recent rapid advances in molecular biology. Mutations identified
in humans can be incorporated into ion channel gene cDNA, the mutant channel
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expressed in a cell membrane and the current across the mutant channel measured.
These functional studies not only provide insight into the basic physiology of disease
but may suggest novel therapeutic pathways. Functional studies on different channel
types are discussed in the relevant chapters. Natural and genetically modified animal
models of several channelopathies exist. The channelopathies are therefore an
important source for translational research.
1.1.1 Structure andmolecular biology of ion channels
There are two major classes or superfamilies of ion channels, voltage gated and
ligand gated. Molecular genetic studies have shown that these two classes are
structurally dissimilar. Amino acid sequencing suggests that the voltage-gated K+,
I 2"b # *Na and Ca channels are all members of a family of proteins that are closely related
to each other in evolutionary terms. It is likely that K+ and Ca2+ evolved from a single
I
cation gene and that Na channels developed from Ca channels (Hille 2001). The ion
channel families are large with many closely associated channel species. Because of
their critical role in electrical signalling in the nervous system the structure and
amino acid sequence of large parts of the channel proteins are conserved through
several species from drosophila to man. Most ion channels are assembled from
distinct subunits each coded for by different genes (heteromultimers) though
homomultimers do exist. The voltage gated channels are made up of large a subunits
which make up the channel and may interact with smaller (3
subunits which may play a role in regulating channel function. The ligand gated
channels comprise three major families; nicotinic receptors, glutamate receptors and
the ionotropic ATP receptors.
Ion channels can be regarded as excitable molecules which allow passage of ions
through changes in conformation in response to a variety of stimuli. The action
potential along a nerve, as described by Hodgkin & Huxley, is transmitted by the
sequential depolarisation and repolarisation of the cell membrane by the passage of
sodium and potassium ions across the membrane (Figure 1.1). Changes in membrane
voltage cause voltage gated sodium channels to open allowing a rapid influx of ions
across the membrane with resultant depolarisation. This change in membrane voltage
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leads to the opening of potassium channels and the rapid passage of potassium ions
out of the cell resulting in repolarisation of the membrane (Figure 1.2).
When the action potential reaches the neuromuscular junction a sequence of events
leads to release of acetylcholine (the ligand) which binds to the acetylcholine
receptor, a ligand gated ion channel, on the postsynaptic membrane. The binding of
the ligand leads to a change in conformation of the protein and opening of the
channel allowing sodium ions to pass across the membrane and set in motion the
train of events leading to muscle contraction (Figure 1.3).
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Figure 1.1
The generation of the action potential.
The action potential V is generated by the sudden influx of Na+ ions across
the membrane through voltage-gated sodium channels (a) with resultant
depolarisation of the cell membrane. The opening of voltage-gated potassium
channels allows passage of K+ ions across the cell membrane (b) out of the
cell and re-polarisation of the membrane (Hodgkin & Huxley 1952).
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Figure 1.2
Cartoon of voltage gated ion channel. >4s the membrane voltage changes this
is detected by a voltage sensor within the channel which changes








Cartoon of a ligand gated ion channel. A ligand such as a neurotransmitter
binds to a receptor portion of the channel causing a change in channel





There are over 50 genes which encode mammalian K+ channels and many of these
have multiple isoforms. The group most strongly associated with neurological
disease is the 6 transmembrane domain family of K+ channels. These include the
voltage-gated and calcium gated K+ channels. Potassium channels set the resting
membrane potential and repolarise neurons following action potentials (Kullmann
2002). The voltage gated channels of the Kv family (Chapters 4 & 6) are made up of
four homologous a subunits which come together to make up the channel. The six
transmembrane segments (SI-6) linked by extracellular loops are illustrated in figure
1.4. The S4 region contains positively charged amino acids which cause the channel
to change conformation and open as the transmembrane voltage changes. This region
is called the voltage sensor. The S5-6 linker lines the pore and acts as the selectivity
filter. The N and C terminals have several functions including interactions with other
proteins and in targeting the channel to the cell membrane. Cytoplasmic P regulatory
subunits may also modulate channel function.
1.1.3 Sodium channels
The sodium channel a subunit is associated with two regulatory P subunits as
illustrated in figure 1.5. Sodium channels have four domains each ofwhich is similar
in structure to a potassium channel alpha subunit. Each domain has 6 transmembrane
segments. It is likely that sodium channels evolved (possibly via calcium channels)
from two duplications of the potassium channel (Kullmann 2002). Only one a
subunit is required to form a channel. The S4 segment acts as the voltage sensor with
S5-6 and the S5-6 linker acting as the selectivity filter and the pore forming region
(Catterall 2000a).
1.1.4 Chloride channels




Kv1.1 voltage-gated potassium channel a subunit showing six
transmembrane segments and intracytoplasmic N and C terminals. The loop
between S5 & S6 known as the S5-6 linker is the selectivity filter. The arrow
indicates the position of a point mutation discussed in chapter 4.









Cartoon of sodium channel showing 4 homologous domains in the a subunit
each similar to a potassium channel a subunit, and two regulatory (3 subunits
1.1.5 Calcium channels
Calcium channels have very similar structures to sodium channels with one major
pore forming ai subunit made up of 4 homologous, six segment transmembrane
domains (Catterall 2000b). The structures of sodium and calcium channels differ in
various amino acid sequences and mechanisms of channel inactivation. Calcium
channels have different intracytoplasmic regulatory subunits the ao5 and (3 subunits.
The cbd subunit consists of a single transmembrane segment and is thought to be
important in controlling surface expression of the channel.
1.1.6 Nicotinic ligand-gated channels
The nicotinic receptor family comprises GABAa, nicotinic acetylcholine, glycine
and serotonin receptors. Ligand gated channels are also called ionotropic receptors.
Serotonin receptor mutations are not known to be associated with neurological
disease.
Nicotinic receptors are pentameric, meaning they are made up of five subunits as
illustrated in figure 1.6. Each of the subunits contains four transmembrane domains.
The second domain (M2) lines the pore and controls ion selectivity. The
acetylcholine receptors are not very selective between different cation species
(Kullmann, 2002). The glycine and GABAa receptors are selective for small anions
such as bicarbonate and chloride. The N and C terminals are extra cellular in contrast
to the voltage gated channels. The pentamers can be homomultimeric or
heteromultimeric with a variety of subunit types coming together to form the
channel. The GABAa receptor has at least 15 subunit types meaning that there are a
great variety of potential channel combinations. The nicotinic acetylcholine receptors
have fewer subtypes. It is important to note that different subtypes may be expressed
at different periods of development. For example there are specific fetal subtypes of
muscle acetylcholine receptors. This is important when a mother develops antibodies
against fetal subtypes. She may have no symptoms but the fetus may suffer from
antibody mediated attack causing congenital arthrogryposis.
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Figure 1.6
Cartoon of neuronal nicotinic acetylcholine receptor illustrating how a4
subunits combine with /32 subunits to make up the pentameric structure of
the channel.
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1.2 The Neurological Channelopathies
Table 1.1 provides an overview of the central nervous system and neuromuscular
disorders associated with mutations in ion channels. It is remarkable to consider that
the first skeletal muscle channelopathy was described in 1991 and the first central
nervous system channelopathy was described in 1994. Since then more than 40
disorders have been described.
As can be seen from the table a single phenotype may be caused by mutations in
different genes. This emphasises the importance of identifying single large families
to identify genes rather than pooling together multiple small families. Some of these
genes code for different subunits of the same ion channel whereas in other cases
genes from a different class of ion channel, such as in Genetic (Generalised)
Epilepsy with Febrile Seizures plus, may associate with the same disorder. This
suggests different genes may be involved at different points in the same pathway or
network that controls neuronal excitability.
This list will continue to grow. I have not included some reports of association of an
ion channel mutation with a single case unless this has been replicated.
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Table 1.1
Central nervous system and neuromuscular channelopathies. Adapted from
Zuberi (2003)
Central Nervous System /Neuromuscular Channelopathies
Central nervous system channelopathies
Disorder Mode of
inheritance


































































Hyperekplexia AD, AR 5q32 GLRA-1 Glycine receptor
al subunit





4q31.3 GLRB Glycine receptor (3
subunit





AD 20ql3.3 KCNQ2 Potassium channel
subunit
Singh et al (1998)
Dedek et al (2001)
Benign familial
neonatal seizures






type 1 +/- epilepsy







AD 10q22.3 KCNMA1 Subunit ofBK
channel
Du et al (2005)
Epilepsy &
neonatal diabetes
AD 11 pi 5.1 KCNJ11 Pore forming unit
of potassium
channel




AD 2q22-23 SCN2A Sodium channel
a.2 subunit





























































AD 19p 13 CACNA1A Calcium channel Zhuchenko et al
(1997)
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Skeletal Muscle and Nerve Channelopathies
Disorder Mode of
inheritance




AD 17q23 SCNA4 Sodium channel a
subunit
Rojas et al (1991)
Paramyotonia
congenita



















































Quane et al (1993)
Central core
disease
AD 19ql 3.1 RYR1 Calcium channel-
ryanodine receptor
Quane et al (1993)
Stationary night
blindness






















































AD 2q24-q32 CHRNA Acetylcholine
receptor (AChR)
a subunit











Ohno et al (1995)
Fast channel
syndrome




AR 17pl3 CHRNE AChR e subunit Engel et al
(1996b)
AR: autosomal recessive; AD: autosomal dominant; X: X-linked
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1.3Mutations in ion channel genes
Human DNA is constantly subject to mutation. Mutations drive the evolutionary
process but they can also be pathogenic, either directly causing a disease phenotype
or increasing the susceptibility to develop a disease. Large scale mutations involve
loss or gain of chromosomal material. Smaller scale mutations can be grouped into
three classes (Strachan & Reid, 2004). These are base substitutions (usually single
bases), deletions of one or more nucleotides or insertion of one or more nucleotides.
Each time a human cell divides a sequence of 6 billion nucleotides needs to be
replicated. Despite the presence of proofreading exonucleases in DNA polymerases
to prevent insertion of incorrect bases, this can occur in DNA replication
Novel mutations can arise in the somatic cells or in the germline. Germline
mutations are more common in the male germ line. We have recently shown in
collaboration with colleagues in Australia that this is the case with mutations
affecting the gene encoding the al subunit of the neuronal sodium channel (SCN1A)
in infants with Dravet syndrome and related epileptic encephalopathies (Heron et al
2009).
There are several mutation types that can occur in ion channel genes including
(Strachan & Read 2004):
• Deletions from one base pair to whole gene
• Insertions and duplications
• Frameshifts- small deletions, insertions or splicing errors adding or removing
nucleotides that are not an exact multiple of three
• Dynamic mutations - tandem repeats that often change size on transmission
to children
Single base substitutions
- Missense mutations replace one amino acid with another in the gene
product
- Nonsense mutations replace an amino acid codon with a stop codon
- Splice site mutations create or destroy signals for exon-intron splicing
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Missense mutations can be conservative or non conservative substitutions depending
on whether the amino acid is replaced by another similar to it. The change may result
in a change in polarity of the amino acid coded for, a change in composition, or a
change in volume. The degree of the physico- chemical change produced by a
missense mutation can be scored in various ways (Grantham 1974). Deciding
whether a particular mutation is pathogenic however is not straight forward and
relies on a hierarchy of evidence (Strachan & Reid 2004):
• Functional expression studies show the change is pathogenic. At present this
is only practical when performed in the research setting. Functional studies
may give misleading results and results may differ in different biological
systems.
• The change has been seen before in individuals with the same phenotype and
not in controls
• Mutation is de novo in a de novo disease
• The sequence change is not seen in large number of controls
• Nature of the mutation
- Whole gene deletions, nonsense mutations and frameshifts will almost
certainly destroy gene function
- Mutations affecting GT.. .AG nucleotides at exon-intron boundary
usually abolish gene function.
- Does the missense mutation occur in a functionally important part of
the gene?
- Is the amino acid conserved in other similar proteins and in other
species?
- Is the amino acid change polar to non polar or acidic to basic?
Assessing the evidence as above is usually sufficient in clinical practice, without
having to use functional studies, in order to judge whether a sequence change
detected is significant or not.
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Chapter 2
Aims of This Work
The aims of this work are to advance the understanding of ion channel disorders
(channelopathies) affecting the nervous system through studying the phenotypes of
individuals and multi-generation families presenting to child neurology. By
collaboration with molecular genetic colleagues in various centres around the world
and latterly in Glasgow, I hope to advance the knowledge of phenotype genotype
relationships in the channelopathies and the understanding of the underlying
physiology of these conditions. I aim to assess whether close collaboration between
clinicians and molecular geneticists can aid diagnosis and influence the management
of patients.
2.1 Specific aims
1. To provide a phenotypic description of epilepsy in the syndromes of episodic
ataxia type 1 and 2 and collaborate with colleagues to better understand the
physiological relationships between epilepsy and movement disorders.
2. To describe the phenotype associated with a potassium channel mutation in a
pure neuromuscular disorder.
3. To describe the genotype-phenotype relationships in benign familial neonatal
seizures.
4. To compare the phenotypes of large families with frontal lobe epilepsy with
mutations in two different but related ion channel gene subunits.
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5. To describe the phenotypes of sodium ion channel a subunit (SCN1A) gene
related infantile epileptic encephalopathies. To evaluate whether establishing





Methods specific to individual disorders studied will be described in the relevant
chapters.
3.1 Ascertainment of cases and families
The vast majority of individuals and families have been ascertained from the
personal practice of the author and his supervisor, Professor John Stephenson. They
comprise children and families presenting to the Fraser ofAllander Neurosciences
Unit (FANU), Royal Hospital for Sick Children, Glasgow. This work has continued
over several years ofmy clinical practice, first as a Senior Registrar and then a
Consultant in Paediatric Neurology in the FANU.
One family with Autosomal Dominant Nocturnal Frontal Lobe Epilepsy was
ascertained through discussion with colleagues in Dundee. Cases have been referred
to the Epilepsy Genetics Service in Glasgow for both molecular genetic analysis and
a clinical opinion from throughout the United Kingdom and many overseas
neurology centres.
3.2 Family studies
In many of the genetic channelopathies there are several affected individuals in a
family. Indeed the diagnosis of a particular disorder may be dependant on identifying
50
a family history. When appropriate to the clinical care of the proband or for the study
I reviewed the family history in detail. I found that identifying the oldest living
female relative, or matriarch, in large families was often the most helpful initial step
in ascertaining the presence and extent of a wider relevant family history. If other
individuals were affected, with appropriate consent of the individual and managing
clinician, I undertook telephone interviews, personal interviews and case record
reviews. When individuals were referred from rural parts of Scotland and preferred
local review I travelled to them.
3.3 Clinical evaluation
As most of the cases studied were seen in routine clinical practice the evaluation was
that of a comprehensive history and neurological examination. Additional tests were
performed as clinically indicated.
Many of the channelopathies present as paroxysmal disorders with a potentially wide
differential diagnosis, and few if any interictal clinical signs or abnormalities on
additional tests. A detailed history is therefore paramount. I took a structured general
history including:
Pregnancy, birth and developmental history
General medical history
Detailed family history including drawing a pedigree
Social and educational history
The history of events, whether epileptic or non-epileptic, was taken from the affected
individual relaying their own experience of the event and from witness accounts. The
history included:
When did the event occur?
What was the individual doing at the beginning of the event?
Were there any triggers to the event?
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What did the individual feel at the beginning of the event?
A detailed description of the event from a witness
Did the individual have a warning of the event?
A detailed description of the event from the individual themselves
Duration of the event - including using techniques such as "replaying events in the
minds eye" to assess timing
Aftermath of the event
Frequency of events
Videotape recordings taken at home were reviewed. In some cases videotape
recorders (and tripods for nocturnal events) were lent to families to capture events at
home. Videotape was also used in the clinic if it was possible to provoke an episode
using special techniques.
I undertook a neurological and relevant general examination of individuals seen in
clinical practice and examined other family members if it contributed to the
diagnosis of that individual. Relevant clinical signs were videotaped.
Neurophysiological investigations were performed as clinically indicated. These
included EEG studies in channelopathies associated with epilepsy and EMG in
disorders affecting nerve and muscle. Video-EEG telemetry studies were required for
diagnostic purposes in selected cases.
I classified individuals with epilepsy, when possible, using the diagnostic scheme
and International League Against Epilepsy Classification of Seizures of Seizures and
Syndromes (Engel 2001, Commission of Classification and Terminology of the
International League Against Epilepsy1989). It is not always possible to make a
syndromic diagnosis using the ILAE classification but when possible I did so.
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3.4 Collaboration with clinicians & molecular genetic labs in
other institutions
The clinical work detailed in the thesis was performed in Glasgow. I have not
undertaken any laboratory work myself though more recently I have supervised staff
working in a molecular genetic service (see below). I have identified the patients and
collaborated closely with genetic scientists to interpret and discuss the relevance of
any molecular findings.
The channelopathies have been emerging as clinically important over the last decade.
Many of these conditions are individually rare and therefore in the last ten years
molecular genetic diagnostic analysis has been largely offered on a research basis by
different laboratories around the world. A laboratory may have specific interests in
certain conditions or genes.
Depending on the clinical condition studied I have collaborated closely with
clinicians and scientists in different international centres. More recently as the
importance of the channelopathies has been appreciated molecular genetic analysis
for some conditions has been offered on a service basis.
In studies ofEpisodic Ataxias Type 1 and 2 I have collaborated with Professor Mike
Hanna, Professor Nick Davis and Professor Dimitri Kullman at the Institute of
Neurology, Queen Square, London. They have undertaken molecular genetic
analysis of the potassium channel genes Kvl.l and calcium channel gene
CACNA1A. Their laboratory has also undertaken functional studies of the mutations
detected in the individuals I have studied.
In studies of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy, Benign Familial
Neonatal Seizures, Benign Familial Infantile Convulsions and Paroxysmal
Dyskinesia and Dravet Syndrome I have collaborated with Professor Ingrid Scheffer
and Professor Samuel Berkovic at the Austin Medical Centre in Melbourne and
Professor John Mulley at the Women's and Children's Hospital in Adelaide. Their
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labs have undertaken genetic analysis of nicotinic acetylcholine receptor genes
CHRNA4 and CHRNB2, potassium channel subunit genes KCNQ2 and KCNQ3,
and sodium channel gene SCN1A. Functional studies on mutations in CHRNA4 and
CFIRNB2 were undertaken by Professor Daniel Bertrand's laboratory in Geneva.
PET studies of Scottish patients with ADNFLE were undertaken by Dr Fabienne
Picard and colleagues in Paris.
In studies of children with hyperekplexia I have collaborated with Professor Mark
Rees at the University of Swansea and Professor Robert Flarvey at the School of
Pharmacy in London. They have undertaken genetic analysis of the glycine
transporter gene SLC6A5 and functional studies of mutations detected in cases I
have identified.
3.5 Establishing an Epilepsy Genetics Service - molecular
genetic diagnostic lab and clinical service - in Glasgow
Having worked with a research laboratory in Australia for several years, studying
severe infantile onset SCN1A gene related epilepsies such as Dravet Syndrome I felt
that this was likely to be the most clinically relevant gene and one which should be
offered more widely on a service basis. I was successful in obtaining a grant from an
epilepsy charity, The Muir Maxwell Trust, to purchase a DNA sequencer and support
running costs of an SCN1A genetic diagnostic service. This is a joint clinical and
molecular genetic service based at the Fraser of Allander Neurosciences Unit and
Duncan Guthrie Institute ofMedical Genetics both in the Royal Hospital for Sick
Children, Glasgow. We have now secured National Services Division Scotland
funding for the service as well as UK Genetic Testing Network (UKGTN) status.
Australia is one of the countries which now uses our lab for diagnostic testing.
This remains the first and only SCN1A diagnostic service in the United Kingdom
and one of few worldwide. It was important that it was established in such a way to
facilitate audit and research. I developed a clinical form to accompany the DNA
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sample. Referrers complete the form which I review prior to genetic testing. Given
the complex genotype phenotype relationships in SCN1A related epilepsy this allows
us to report the results of genetic testing in the context of the clinical referral
information. We have ethical approval to audit and publish results of the molecular
service and ethical approval for a study of genotype phenotype relationships using
data from the referral form.
3.6 Ethical aspects
All participating individuals, or carers in the case ofminors, gave informed consent.
Confidentiality was preserved for all subjects. Many individuals and families were
seen in routine clinical practice. Written or recorded verbal consent (on video) was
obtained for the use of photographic or video recordings. Case record review was
approved by the Royal Hospital for Sick Children, Glasgow, Ethics Committee.
Ethical approval for genotype phenotype studies was obtained from the National
Research Ethics Service, Scotland A Research Ethics Committee. The review of




Episodic Ataxia Type 1 and Epilepsy
4.1 Introduction
Episodic ataxia type 1 (EA1) is a rare autosomal dominant movement disorder in
which patients develop sudden brief episodes of paroxysmal ataxia (Van Dyke et al
1975). EA1 is associated with point mutations in the voltage-gated potassium
channel gene (KCNA1) on chromosome 12pl3. EA1 (Browne et al 1994, Litt et al
1994).
In this chapter I describe the clinical study of three Scottish families with this
disorder and summarise collaborative work on these families undertaken by
colleagues at the Institute ofNeurology, Queen Square, London. The clinical and
genetic study of family A has been published in Brain and has provided insights into
the pathogenesis of the ataxia and epilepsy (Zuberi et al 1999). The links between
epilepsy and movement disorders are discussed. The studies on families B and C
support the original observations linking episodic ataxia type 1 and epilepsy with
mutations in the KCNAI gene. The study provides new insights into the phenotypic
variability present within families. This relatively rare disorder can provide insights
into pathophysiology of common neurological diseases such as epilepsy
The KCNAI gene codes for the Kvl.l potassium ion channel (Browne et al 1994).
The widespread expression of this channel in cerebellum, cerebral cortex and
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peripheral nerve helps explain the symptoms associated with this disorder. Kvl .1 is a
delayed rectifier potassium channel which has a key role in allowing the cell
membrane to repolarise following an action potential and controlling neuronal
excitability. It comes from the Shaker family ofpotassium channels which are highly
conserved throughout evolution, with homologous channels in drosophila, mice and
humans (Ramaswami et al 1990). Kvl.l channels are tetrameric, consisting of four
pore-forming subunits, each ofwhich contain six transmembrane segments, linked
by intracellular and extracellular loops (Ashcroft 2000).
EA1 usually has its onset in childhood and is characterised by brief episodes of
cerebellar ataxia and dysarthria. The other key clinical feature is interictal myokymia
also termed neuromyotonia. Some individuals describe a brief aura before the event
such as a rising sensation up the body warning them that they will have to hold onto
something for support. The ataxia may be associated with a coarse tremor and the
movements may have features of chorea or dystonia. Some individuals describe
weakness during an attack (Klein et al 2004).
In between attacks there is no interictal ataxia. Myokymia, the clinical sign most
useful in making the diagnosis, may be subtle and missed if not looked for
specifically. It is best observed as semi-rhythmic side to side movements of the
fingers with the hands outstretched or as rippling of the muscles of the lower eyelid.
Continuous motor unit activity can be demonstrated by surface electromyography
without the necessity for needle insertion.
4.2 Methods
4.2.1 Clinical Studies
The probands from the three families were all referred for evaluation of paroxysmal
events to the Fraser ofAllander Neurosciences Unit (FANU). All families were of
Scottish descent except for the mother of case II in family A, who was ofGerman
descent. The disease was documented over three generations in all 3 families. The
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diagnosis of EA1 was based on the appropriate clinical history and the presence of
myokymia on clinical examination and/or electromyography (EMG). The clinical
evaluation of affected family members, children and adults, was undertaken by
myself and followed the methods outlined in chapter 5. Some of the adults had
imaging investigations undertaken at the Southern General Hospital in Glasgow.
Case records were reviewed, including GP records and RHSC records from the
1960s held on microfiche. The diagnosis of epilepsy was based on the clinical
history and witness account and was supported by ictal video- EEG in one case.
EMG was performed on four patients from family A and one member each from
families B and C. Video recordings were made of all individuals who were
examined. Ataxic episodes were induced and recorded in two patients from family A
and home video of several ataxic episodes was available for one member of family
B.
EEG studies were performed in the EEG department, Royal Hospital for Sick
Children, Glasgow and interpreted by Professor John Stephenson and myself in
family A and by myself in families B and C. EMG studies were performed by Dr
Robert McWilliam and Dr Iain Horrocks, Consultant Paediatric Neurologists, Royal
Hospital for Sick Children, Glasgow.
4.2.2 Molecular Genetic & Functional Studies (Work
undertaken in London)
Informed consent was obtained for DNA analysis from all nine individuals in family
A, 2 individuals in family B and 5 in family C. DNA was extracted using standard
methods in Glasgow and forwarded to colleagues at the Muscle and Neurogenetics
Sections, Institute ofNeurology, Queen Square, London.
Louise Eunson under the supervision of Professor Mike Hanna and Professor Nick
Wood undertook the sequencing of the KCNA1 gene in family A. Alex Spauschus
worked on functional studies of family A under the supervision of Professor Dimitri
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Kullmann. Human KCNA1 wild-type and mutant genes were amplified using PCR
on genomic DNA extracted from a blood sample from one of the affected family
members. Using cDNA techniques wild type and mutant clones were sequenced and
transcribed in vitro. The mutant and wild type channels were expressed on Xenopus
oocytes and patch clamp techniques used to measure currents across the channels.
The mutant and wild type channel gene subunits were also expressed together in
varying proportions to make up heterotetrameric channels.
DNA sequencing and haplotype studies from families B and C were performed by
Tracey Graves under the supervision of Professor Mike Hanna. Tracey Graves and
Stephanie Schorge undertook functional studies of the mutant channels in human
embryonic kidney (HEK) cells in Professor Kullmann's laboratory.
4.3 Results
4.3.1 Clinical study on family A
The pedigree is detailed in figure 4.1.
Case III2
The proband is a 3—year old boy who presented aged 7 weeks with recurrent
apnoeic episodes associated with cyanosis. Pregnancy and delivery were
unremarkable and the only abnormality noted prior to these episodes was a tendency
to keep his fists clenched. Neurological examination was normal. Interictal EEG was
normal. A 24-h video EEG study was performed during which several episodes were
captured. These were shown to be focal epileptic seizures with impairment of
awareness (complex partial seizures). Recordings showed the child staring forward
or with his head turning to the left, the eyelids flickering, lip-smacking and the
development of cyanosis. The episodes lasted up to 2 minutes and terminated with
the infant fixing on his mother and the onset of regular respiration. EEG changes
during the episode
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Figure 4.1 Pedigree of family A. Taken from Zuberi et al (1999).
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Fig. 1 Upper panel. Pertinent part of ihe pedigree of the
HA 1 /epilepsy family. Filled svmbols indicate individuals with
HA 1. T tie two individuals with epilepsv are indicated bv "Ep"
The lower panel shows an agarose gel containing the DMA
fragments following digestion with the restriction endonuclease
Ddel. Normal individuals have the upper band only i 159 bp
undigested mismatch PGR product as described under Subjects
and methods) as shown for cases II! and 113 (cases 12 and 115 did
not harbour the mutation: data not shown). The presence of the
C677G mutation introduces a restriction site in the affected
individuals (cases 11. 112. 114. III!. 11121. and two bands are
visible in these cases. These are the upper band, which is the
undigested 159-bp product, and the lower band, which is the
larger 131 -bp product of digestion. The smaller 28-bp product of
digestion is not shown. Lane 1. case Till; lane 2. case HI; lane 3.
ease 112: lane 4. ease 1112: lane 5. case 113: lane h. case II; lane 7.
case 114. The proband (case III 2) is indicated bv an arrow.
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consisted of rhythmical slow wave activity over the right hemisphere (possible right
temporal lobe onset), becoming spike and slow wave complexes (Figure 4.2). This
activity then spread to the left hemisphere, and asynchronous flattening of rhythms
occurred periodically over both hemispheres. A CT scan with angled cuts through the
temporal lobe was normal. Plasma electrolytes, calcium and magnesium were
normal. The patient was treated with carbamazepine and had no further epileptic
seizures. Subsequent developmental progress was normal and anti-epileptic
medication was stopped at the age of 2 years.
At 20 months he developed irritability and swelling of his hands and feet. He had
clenched fists and flexion of the toes. The dorsum of his hands and feet appeared
swollen and oedematous and he refused to walk. Investigations for renal and joint
disorders were negative and the problem resolved within a few days.
At the age of 2 years episodes of unsteadiness when walking developed. His legs
would appear to buckle under him. There were several months between attacks and
interictal general and neurological examination were normal. From the age of 3 years
he has had episodes of ataxia at least once a week lasting seconds to minutes,
precipitated by startle, exercise and sudden movement. Consciousness is preserved in
the attacks. Examination shows periorbital and finger myokymia. Surface EMG
shows continuous motor unit activity (Figure 4.3). The repetitive rhythmic
discharges were heard clearly and recorded on videotape during the EMG. EEG at 3
years is normal.
Case II
The 50 year old paternal grandmother of the proband has had symptoms of ataxia
since early childhood. They are precipitated by sudden movements, exercise, anxiety
or loud noises, or occur spontaneously and last seconds to a few minutes. During
episodes she becomes ataxic, has dysarthria but retains full consciousness.
Phenobarbitone therapy as a child was not helpful. She attended a school for children
with mild to moderate learning difficulties.
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Figure 4.2. Ictal EEG of case 1112, family A showing a focal sharp and slow
wave activity with onset in right temporal region spreading to the left
hemisphere. These changes were associated with an epileptic apnoea.




Figure 4.3. Surface EMG in case 1112 showing rhythmic continuous motor unit
activity
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Clinical examination is normal apart from perorbital and finger myokymia.
Acetazolamide was unhelpful.
Case 112
The 31 year old father of the proband was noted to have postural abnormalities of his
upper and lower limbs at the age of 3 months when admitted with bronchiolitis. His
wrists were flexed, the thumbs were adducted across his palms and his feet were held
in equinovarus. There was no spasticity on examination. He was treated with splints.
During this acute illness he developed transient oedema of his extremities. He was
noted to have twitching of his eyelids but an EEG was normal. At 5 months he had
surgery for a strangulated inguinal hernia. He walked at 14 months and his foot
deformity had resolved, but he had a continued tendency to adduct his thumbs across
his palms.
Episodes of ataxia began at the age of 4 years. They occur spontaneously, after a
sudden movement or are precipitated by exercise. The attacks last seconds to
minutes. Clinical examination showed myokymia, which was most prominent in the
fingers and peri-orbital area. A typical ataxic episode, which lasted ~ 2 minutes was
recorded on video after he was asked to walk briskly up a flight of stairs. He was
markedly ataxic with dysarthria but eye movements were normal. EMG showed
continuous motor unit activity consistent with myokymia. An interictal EEG was
normal apart from showing prominent muscle activity with EMG at a frequency of
~10/s, which was more prominent with hyperventilation (Figure 4.4). A 1.5T MRI of
brain and cerebral perfusion SPECT scan were normal. Acetazolamide produced
resolution of attacks for 3 months but they returned at a reduced frequency. Attacks
tend to cluster.
Case 114
This 30 year old woman has EA1 and epilepsy. She presented in early infancy with
more prominent postural deformities of her limbs than in her brother. Her wrists
were flexed to 50°, her thumbs were adducted and her knees were flexed to 20° and
her feet were held in an equinovarus posture. Serum creatine phosphokinase was
63
normal. An EEG in infancy was normal. A diagnosis of atypical familial
arthrogryposis was made. Like her brother she required surgery for an inguinal
hernia. She walked late at 2 years of age and by 3 years the postural abnormalities
had almost completely resolved. At the age of 9 years she was diagnosed as having
stage IV Hodgkin's disease. She responded to chemotherapy and localised
radiotherapy and since then she has been disease free.
At the ages of 9 and 10 years she began to have epileptic seizures and episodic ataxia
respectively. The clinical features of the seizures suggest they are focal seizures with
impairment of awareness (complex partial) followed by secondary generalisation.
There is no warning and the onset involves turning her head to the right accompanied
by impaired awareness lasting up to 30 seconds followed by a generalised tonic
clonic seizure. EEG and CT brain were normal at the age of 9 years. The ataxic
episodes are clearly distinguished from the seizures and are similar to those
described in her mother and brother. Consciousness is fully preserved. Neither the
epileptic seizures nor the ataxic episodes have responded to phenytoin or sodium
valproate. On examination she has periorbital and finger myokymia. EEG aged 29
was normal apart from prominent muscle artefact.
Case III1
This ten year old boy was also born with the postural abnormalities as described in
other family members. At 8 months his fingers were held flexed and this would
interfere with attempts to grasp and transfer objects. His knees were held slightly
flexed (Figure 4.5). At 10 months, during an inter-current illness, he developed
peripheral pitting oedema of his hands and feet, which resolved. By 14 months the
postural abnormalities had resolved and he could cruise around furniture. At the age
of 4 years he began to have typical ataxic episodes lasting from seconds to a few
minutes. At age 10 an ataxic episode was videotaped in the hospital. It was induced
by asking him to repeatedly step off a library stool. After 3 or 4 steps off the stool he
could not speak, became very ataxic, lurching forward and having to be held by his
father. The event lasted just a few seconds. EEG shows regular muscle activity more
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Figure 4.5. Case 1111, family A in infancy. Flexed posture of knees, equinus
posture at ankles and clenched fists are due to neuromyotonia.
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prominent after hyperventilation but no other abnormality. EMG shows myokymia.
Carbamazepine produced an initial decrease in ataxic episodes but this was not
sustained.
4.3.2 Genetic and functional studies in family A
DNA sequence analysis of the KCNA1 gene revealed one significant heterozygous
change, a C—»G transition at position 677. This was not detected in 200 control
chromosomes, it segregated with the disease and resulted in a radical amino acid
substitution, threonine —* arginine at position 226. This is a highly conserved
position in the second transmembrane segment of the channel (Figure 4.6).
Expression studies showed that the mutant channel could be correctly translated and
processed to the Xenopus oocyte cell membrane but it yielded currents with a
significantly reduced amplitude, ~3%, compared with wild type. It was co-expressed
with wild type channels to try to model the heterozygous state in vivo. The mutant
allele seemed to dominate over the wild type with respect to current amplitude. This
dominant negative effect is illustrated in figure 4.7
4.3.3 Clinical study of family B
The pedigree is detailed in figure 4.8. There are 5 affected individuals ofwhom I
have seen and examined 2 individuals.
Case IV1
The proband was referred to my paroxysmal disorders clinic for evaluation of
possible epileptic seizures and dizzy turns aged 13y. His first events began around
the age of 6 months. He would stop all activity, his lips would go blue, his face pale,
his eyes would roll up and would he lose tone and slump to one side. The whole
episode lasted one to two minutes. They occurred about once every two months. He
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Figure 4.6 Cartoon showing T226R mutation in S2 segment of the of Kv1.1




Figure 4.7 Amplitude histogram showing whole cell currents in Xenopus
laevis oocytes co-injected with wild type and mutant T226R channels. The
mutant channels demonstrate a dominant negative effect.
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67
was seen in the local hospital. An interictal EEG was normal. No diagnosis was
made and the family stopped attending the hospital
after about 2 years of age despite the events continuing until he went to school
Around five years of age he began to have episodes he describes as "jelly legs".
These continue to occur most days with a frequency of up to 3 per day. The episodes
are triggered by sudden movement such as tripping over feet, anxiety, sitting down
and then trying to stand after exercise such as playing football. He feels a tingling
sensation rising up his legs. Sometimes he tries to think of something to prevent the
event progressing. This rarely helps. He feels unsteady as if he is going to fall, has to
hold onto something for support and then his arms and legs start to shake. He
staggers if he tries to walk. He remains fully aware. He has some dysarthria. The
whole events lasts 30 seconds to 5 minutes. His mother managed to capture several
events on home video. He is standing with a broad base but clearly ataxic with a
coarse tremor ofhis upper limbs and titubation of his head. He is clearly aware and
appropriately responsive in the events.
About once per month a typical unsteady episode progresses into a secondary
generalised epileptic seizure. He collapses to the floor, is unconscious and has
generalised clonic movements of all limbs. This lasts about 2 minutes. He has bitten
his tongue in one event. Following the event he is confused. Neurological
examination is normal apart from finger and eyelid myokymia. He has no
educational difficulties. A standard EEG, sleep deprived EEG and 24h ambulatory
EEG were normal. He had an episode of ataxia during the 24h EEG with no EEG
change.
Lamotrigine and carbamazepine did not decrease frequency of either episodic ataxia
or epileptic seizures. Acetazolamide has controlled the epileptic seizures but the
frequency of episodic ataxia has reduced but still occurs about 5 times per week.
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Figure 4.9 Pedigree of family C
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The proband's 44 year old father had brief episodes of ataxia from early childhood
until about 15 years of age. He said that they were triggered by sudden movements
and would last a few seconds to a minute. He retained consciousness throughout
them. He did not seek medical advice. He has finger and eyelid myokymia evident
on examination.
Other affected family members
I did not directly interview or examine the other family members. The history of their
events came from case 112. The uncle of the proband, case III 1, was reported to have
had "dizzy turns" from childhood which continue as an adult. He is employed as a
driver. He stops driving during an attack. He carries a supply of chocolates and
sweets with him as he feels that taking something to eat stops an event. Case 112 only
discovered this about his brother having similar episodes to himself during the
evaluation of his son. The paternal grandmother, case 112, is also reported to have
had "dizzy turns" since childhood and possibly epileptic seizures in her 20s. She
lives in the USA and has apparently had extensive investigations with no diagnosis
for her dizzy turns. The paternal great aunt of the proband, case 113, lives in Scotland
and is also reported to have had brief "dizzy turns" since childhood. She has never
been investigated and does not wish to be.
4.3.4 Clinical Study of family C
The pedigree is detailed in figure 4.9. There are 10 affected members ofwhom I have
seen and examined 5 individuals over three generations. 2 cousins, cases III3 and
III 13, from this family were independently referred to my clinic for assessment of
paroxysmal events.
Case III3
This 19 year old girl began having events age 6 or 7. They are triggered by sudden
movement and emotion. They can occur spontaneously and in an intercurrent illness
she can have up to 30 per day. She has events most days. They last seconds to up
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to 20 minutes. She feels unsteady and has to hold on to someone or to a fence so she
does not fall. She has dysarthria during episodes and has been stopped by police and
accused of being drunk during an episode. Age 15 she had three episodes of collapse.
One of these sounded clinically like a syncope. In two events she had a brief
warning and then lost consciousness for a period followed by post ictal confusion
and lethargy for about twenty minutes. One witnessed episode lasted 2-5 minutes.
The history suggested a generalised tonic clonic epileptic seizure. An EEG was
normal. On examination she has finger and eyelid myokymia. She has been treated
with carbamazepine and acetazolamide these have not reduced the frequency of
ataxic episodes.
Case III 13
This 14 year old boy had neuromyotonia in early infancy. He tended to keep his arms
flexed and fists clenched. This resolved by about a year of age. At about 1 year he
had a generalised clonic febrile seizure. The clonic movements lasted between 5 and
ten minutes. He began having brief episodes of ataxia lasting seconds to a few
minutes aged 6 years. These are triggered by movement, startle or exercise but can
occur spontaneously. They occur on most days and during intercurrent illnesses can
almost be continuous throughout the day. A 24h EEG was normal. He has finger and
eyelid myokymia. He has mild to moderate learning disability and attends a special
needs school. His ataxic episodes have shown a partial response to carbamazepine.
Case II
This 64 year old lady has had episodes from about 12 years of age. They can be
triggered by sudden movement such as getting up from a chair but also occur
spontaneously when sitting or lying in bed. She feels unsteady and describes herself
as "legless". She has to hold onto something. Her voice becomes slurred. The
episodes last from a few seconds to minutes. The longest was 10 minutes. At present
they occur once a week but have occurred daily in the past. She has never seen a
doctor about the events. There is no history of neuromyotonia when unwell. On
examination she has finger and eyelid myokymia. None of her children had a clear
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history of infantile neuromyotonia. She had 13 siblings and was not aware of any of
them having similar episodes to herself.
Case 119
This 38 year old has had episodes from 7-8 years of age. The events are triggered by
getting up too quickly or sudden movements. Her speech slurs and she feels dizzy.
At the onset she feels a rising sensation coming up through her body. Attacks can last
seconds to up to 10 minutes. During attacks she has to hold on to something. She
had a bad attack when she was younger when dancing and wearing high heels
causing her to fall and break a bone in her ankle. She has at least one episode a week
but can have multiple episodes in a day particularly when she is unwell with a viral
infection. Attacks may occur without any movement triggers when she is unwell. In
the past her GP treated her for possible epilepsy and prescribed tegretol. It didn't
clearly help and she doesn't take any regular medication. She has collapsed once and
lost consciousness. I thought this was a syncope and not epileptic. On examination
she has finger and eyelid myokymia.
Case II10
This 37 year old lady had events from 7 or 8 years of age. The episodes are triggered
by getting up too quickly, any sudden movement and startle. The events are
described as dizzy episodes. Her speech is slurred and she has to hold on to
something or sit down. Sometimes they occur without any clear trigger when she is
lying in bed. This is more common if she is unwell. She has at least 1 per week, but
usually more, and can have a cluster of events in one day. She has never taken
medication and has been told "it was all in her head". On examination she has finger
and eyelid myokymia.
Other family members
I did not interview or examine other family members. The following information is
from their close relatives. Case 114 is the mother of the proband case III3 and
daughter of case II. This 40 year old lady has had "dizzy spells" since early
childhood. These are triggered by movement or stress. Since the diagnosis of her
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daughter she has been on carbamazepine which has helped to a degree. Case 116 is
the twin sister of case 114. She has had "dizzy spells" since childhood. She is on no
medication. Case II12 had dizzy turns from childhood. She died in childhood from a
respiratory illness. Case III5 has events less frequent than other family members.
They only tend to happen when he is unwell. The started in early childhood and last a
few seconds. He has mild learning disability. Case III8, the 21 year old daughter of
116, is said to have similar episodes to her mother. Case III 16 the ten year old brother
of III 13 and son of II10 has had episodes of unsteadiness triggered by movement or
startle since the age of 4 years. He has not received any treatment as yet.
4.3.5 Genetic and functional studies in families B and C
The KCNA1 gene was sequenced in 2 individuals from family B and 5 from family
C. All affected individuals had a novel T to C substitution identified at position 1241
ofKCNA1. This change was not seen in 128 control chromosomes. The mutation
results in the substitution of phenylalanine, a large aromatic residue, for serine, a
small polar residue, at amino acid 414 (F414S). This is at a highly conserved residue
in the S6 transmembrane segment of the Kvl.l channel. As the mutation was found
in 2 apparently unrelated families haplotype analysis was performed. All except one
marker was shared by all the affected individuals from both families. The results
suggested a shared ancestral haplotype on which the mutation has arisen and that the
two families are related. The families live approximately 20 miles apart and are not
aware of any familial link with each others localities.
It was possible to express functional F414S mutant potassium channels in the HEK
cell model. The channels were able to conduct potassium currents but these were
approximately 40% of the wild type. The channels were slower to activate and
inactivated more rapidly than wild type channels. The mutant channels therefore
demonstrated a loss of function compared to wild type.
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4.4 Discussion
4.4.1 Clinical Features and Investigations
In this study I have identified three families with the rare autosomal dominant
disorder EA1 in which some individuals from each family also had epileptic seizures.
Sequencing and haplotype studies suggest that families B and C share a common
mutation in KCNA1 and are in fact related to a common ancestor. Therefore in the
discussion I will refer to them collectively as family BC.
As in other paroxysmal conditions due to ion channel dysfunction, there was a long
delay in making the correct diagnosis. The diagnosis of the three probands led to the
correct diagnosis of an additional 17 individuals none ofwhom had a previous
diagnosis ofEA1. The lack of correct diagnosis is probably not a surprise given the
rarity of the disorder and its paroxysmal nature. A factitious disorder was considered
in at least two individuals. Some of the older affected individuals had events from
childhood and although they continued to have episodic ataxia had become stoical
and accepting of their symptoms and did not seek medical advice. It was also
notable that close family members were sometimes not aware that a sibling or parent
had exactly the same symptoms.
Neuromyotonia with postural abnormalities affected 4/5 individuals in family A but
only 1 individual in family BC. This is presumed to be as a result of continuous
muscle fibre activity. The inguinal hernias in family A were likely to be as a result of
myokymia in the abdominal wall musculature. The postural abnormalities were so
severe that they were termed an atypical arthrogryposis in family A but even more
atypically for an arthrogryposis the postural abnormalities resolved with time. It is
important that surgery is not considered for tendon release in infancy. Prior to the
report of family A (Zuberi et al 1999) postural abnormalities had been described in
one family previously (Hanson et al 1977). Another point of interest (and relevant to
the next chapter) is that the postural abnormalities worsened during acute illnesses in
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three cases in family A and 1 case in family BC. This may be due to acid-base or
electrolyte changes exacerbating ion channel dysfunction.
All individuals had onset of ataxia before 12 years of age. The triggers including
movement, startle, exercise and emotion were typical for EA1 but what has not been
emphasised in previous literature is that many of the individuals can have
spontaneous attacks with no clear trigger even when well. Attacks can occur in bed.
When unwell, individuals in family BC described almost continuous, repeated
attacks through the day. Attacks were usually brief but lasted up to 20 minutes in one
case. During ataxic episodes two teenagers in family BC were questioned by police
officers who thought they were drunk or taking drugs. The attacks captured on video
had some significant differences between individuals. In family A, a father and son
had episodes captured on video. Both appeared slightly distressed during episodes,
they found it difficult to talk, they had a broad based gait and wanted to hold on to
something to maintain standing. Case III 1 lurched forward in the episode and had to
be caught by his father. The home videos of case IV1 showed a prominent coarse
tremor of the limbs and titubation of the head during events.
The most useful clinical sign was myokymia detected in all individuals by
observation of small amplitude, semi-rhythmic, irregular, lateral finger movements
with the hands held outstretched with forearms pronated. Eyelid myokymia was
relatively subtle and seen more easily in the adults than the children. Surface EMG is
a non-invasive way to demonstrate the myokymia (Figure 4.3). The observation of a
continuous rhythmic muscle discharge artefact on EEG recordings in two individuals
in family A was also a clue to the diagnosis. The muscle activity became more
prominent during hyperventilation, perhaps reflecting the effect of changes in pH or
CO2 on channel function.
Overrall the effect ofmedication on symptoms was disappointing. The effect of
medication on epileptic seizures will be discussed in the section on epilepsy below.
Acetazolamide, a carbonic anhydrase inhibitor, was partially effective in controlling
ataxia in 1 member of family A and in two members of family B. Acetazolamide
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may produce its effect by increasing the CO2 in the channel vicinity, causing
hyperpolarisation of the cell membrane and reducing neuronal excitability (Brunt &
Van Weerden, 1990; Lubbers et al, 1995). Carbamazepine, an anti-epileptic
medication and sodium channel blocker, was helpful in reducing ataxia for 3
individuals in family A, but this response was not sustained. It was also helpful in
one individual in family BC. Other anti-epileptic medications including
phenobarbitone and phenytoin have been reported as effective in some individuals in
other families but when tried were not helpful in the families I have managed. These
observations indicate that the variable response to medication may not only be
influenced by the specific mutation in a family but also by the rest of an individual's
genetic and possibly environmental background.
Formal neuropsychological evaluations were not performed on any of the affected
individuals with EA1. 2 individuals in family BC (one with and one without
epilepsy) and one in family A (without epilepsy) attended schools for children with
mild to moderate learning disability. My clinical impression was that several other
family members may have specific learning difficulties but this was not formally
assessed. This is a potential area for further study. The Kvl.l channels are expressed
throughout the nervous system and may have a role in cognitive processing. KCNA1
mRNA is known to be expressed in human amygdala, caudate nucleus,
hippocampus, hypothalamus and thalamus (Albrecht et al 1995).
4.4.2 Molecular genetic and functional studies
There is good evidence that the mutations detected in these three families are
pathogenic. The nature of the mutations as detailed in the results section and the
expression studies support this. The mutant allele from family A could be translated
and processed to the cell membrane of the Xenopus oocyte. The currents were
significantly reduced compared to the wild type channel (Figure 4.7). When
expressed together with the wild type channel the mutant allele seemed to dominate
with respect to current amplitude. Therefore, heterotetrameric channels, as might be
expressed in heterozygous patients, would be expected to have a reduced potassium
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efflux during action potentials. Similar results have been achieved in functional
studies of another EA1 associated mutation (Adelman et al 1995). Delayed
repolarization is therefore likely to be the basis of the neuromyotonia and episodic
ataxia. It is also possible that weakness may result from a depolarisation block.
The clinical, genetic and functional studies of families B and C have not been
published as yet. The functional study ofF414S in HEK cells performed by Tracey
Graves and colleagues is the first we aware of in which mutant Kvl. 1 channels have
been expressed in a human cell line. The mutant channel demonstrates a loss of
function as detailed in the results section above. In many channelopathies expression
studies give conflicting results in different models (Ragsdale 2008). EA1 mutants
seem to be consistently associated with reduced channel function (Graves TD,
personal communication).
4.4.3 The relationship between EA1 and epilepsy
Our 1999 Brain paper was the first to report the relationship between KCNA1
mutations and epilepsy as giving a wider insight into the pathogenesis of epileptic
seizures (Zuberi et al 1999). Family A were the 11th family to be reported with EA1,
comprising a total of 90 affected individuals (Van Dyke et al 1975; Hanson et al
1977; Gancher & Nutt 1986; Brunt & Van Weerden 1990; Vaamonde et al 1991;
Browne et al 1994; Lubbers et al 1995; Comu et al 1996). 8 individuals from three
families, including family A, were reported to have epilepsy. Eunson et al. reported a
family who had a KCNA1 mutation associated with myokymia and epilepsy but not
with episodic ataxia (Eunson et al 2000). The proband was a 40 year old woman who
had tonic clonic seizures from the age of 9 and simple partial seizures from the age
of 19. Her EEG showed sporadic sharp waves and slow waves over the left temporal
region. Her 3 year old son had afebrile generalised tonic clonic seizures. Families B
and C contain a further 2 individuals with recurrent epileptic seizures and one who
has had a single generalised tonic clonic seizure. In all the families with EA1 and
epilepsy none of the individuals who are unaffected by episodic ataxia or myokymia
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have epilepsy. There is therefore a significant overrepresentation of epilepsy in
individuals withKCNAl mutations.
The phenotype of the epileptic seizures in infancy in the proband (III2) from family
A, and the proband (IVI) from family B, are very similar. They appear to be brief
focal epileptic seizures characterised by epileptic apnoea. They might best be
described as benign partial seizures of infancy. Epileptic apnoeas are often associated
with temporal lobe onset epileptic seizures in infancy. Kvl.l is known to be
expressed in human amygdala and hippocampus (Albrecht et al 1995). The seizure
captured in case III2 from family A appeared to have temporal lobe onset. These
seizures are not dissimilar to events seen in the syndrome of benign familial neonatal
convulsions (see Chapter 7). These are known to be associated with mutations in the
potassium channel subunits KCNQ2 and KCNQ3 (Biervert et al 1998; Charlier et al;
Singh et al 1998).
Further evidence that dysfunction ofKvl.l channels can cause epilepsy come from
the mouse knockout for Kvl.l, which has a lethal epilepsy phenotype (Smart et al
1998). Drugs such as 4-aminopyridine that block potassium channels are
proconvulsant in humans (Newsom-Davis 1993; Morales-Villagran et al 1996).
Autosomal dominant lateral temporal lobe epilepsy also known as autosomal
dominant partial epilepsy with auditory features is associated with mutations in the
LGI1 gene. The protein product of this gene has recently been found to be part of a
protein complex closely associated with the Kvl.l protein. Mutations in LGI1 appear
to alter fast inactivation of the channel once again implicating Kvl.l in
epileptogenesis (Schulte et al 2006.
Further evidence that Kvl.l potassium channels are important in the pathogenesis of
epilepsy and neuromyotonia comes from autoimmune limbic encephalitis. In this
condition there is evidence of autoantibodies against the Kvl.l channels (Vincent et
al 2004). These channels are expressed in the limbic system and autoimmune attack
can result in epileptic seizures, encephalopathy and long term cognitive impairment.
Another feature seen in some individuals with limbic encephalitis is myokymia,





In this chapter I describe a Scottish family from the Outer Hebrides with 3 affected
individuals who have familial generalised myokymia. The syndrome of idiopathic
familial generalised myokymia or neuromyotonia had been previously recognised
however this is the first family reported with isolated neuromyotonia caused by a
genetic defect. This work was published in Annals ofNeurology in 2000 in a report




The proband of this family presented to the neurology service, Royal Hospital for
Sick Children, Glasgow as an emergency. Additional family members were studied
on a field trip to the Outer Hebrides and cases were subsequently reviewed in clinic
in Glasgow. I undertook the clinical evaluation of all family members. Dr Robert
McWilliam accompanied me on the field trip. Electromyography studies were
undertaken by my colleagues Dr McWilliam & Dr Iain Horrocks, Consultant
Paediatric Neurologists. The examination of all affected members was videotaped as
were the EMG studies.
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5.2.2 Genetic and functional studies
Molecular genetic studies were undertaken by Dr Louise Eunson under the
supervision of Professor Mike Hanna at the Muscle and Neurogenetics Sections,
Institute ofNeurology, Queen Square, London. Expression studies in a Xenopus
oocyte system (using the methods described in chapter 6) were undertaken by Dr




The pedigree is detailed in figure 5.1. The family were first studied before the birth
of case 113 and she was not included in the publication by Eunson et al (Eunson et al
2000).
Case III
This 3 year old boy was airlifted to the Royal Hospital for sick children Glasgow
from an island in the Outer Hebrides because of a 12 hour history of inability to walk
associated with a 24h vomiting illness. His birth and development had been
unremarkable up until that point apart from intermittent toe walking and running
which his mother had noticed after he first walked aged 18 months. On the day of
admission he had one recorded temperature of 38 degrees celcius but was otherwise
afebrile. He was well perfused with a tachycardia of 160bpm and normal blood
pressure. He was fully alert, answering questions appropriately. He had signs of a
systemic viral infection with enlarged tonsils and injected tympanic membranes.
Cranial nerve examination was normal. There was increased tone in his upper limbs
and his fists were held clenched with thumbs adducted. Small semi-rhythmic
myokymic lateral movements of his fingers were visible. Upper limb tendon
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Figure 5.1 Pedigree of family with generalised myokymia
Figure 5.2 Calfmuscle hypertrophy in siblings with familial generalised
myokymia
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reflexes were present but diminished in amplitude. His knees were held in extension,
and his ankles were plantar flexed. Rippling movements of his calf and hamstring
muscles were palpable and these muscles were visibly hypertrophied. Tone was
increased in his lower limbs. Deep tendon reflexes were diminished at the knees and
not demonstrable at the ankles. There was no percussion myotonia. He did not seem
to be weak. He could stand with minimal assistance but only on the tip of his toes.
Plasma electrolytes, calcium, magnesium, bicarbonate, lactate, ammonia and urea
were normal. Plasma alanine aminotransferase (80 IU/L; normal range, 10-40 IU/L)
and creatine kinase (1,008 IU/L; normal range 15-90 IU/L) were elevated. There was
no myoglobinuria. Muscle ultrasound was normal. Motor nerve conduction velocities
were normal. Surface EMG over the right lateral gastrocnemius and right extensor
digitorum showed continuous motor unit activity (myokymia) even at rest, with a
regular periodicity of about 6 bursts per second.
His vomiting settled, and 24h after his admission, he was walking and running, but
with a toe-to-toe gait. His legs felt less stiff, myokymia was still clinically evident
but rippling movements of large muscles were less evident. Tendon reflexes were
more easily demonstrated. His creatine kinase and other muscle enzyme levels
normalized.
There was no family history of episodic ataxia, epilepsy or neuromuscular problems
however the findings ofmyokymia / neuromyotonia on examination were
reminiscent of that seen in family A with episodic ataxia that has been discussed in
chapter 4. A DNA sample was therefore taken from the proband and forwarded to
colleagues at the Institute ofNeurology, Queen Square.
A year after this acute admission he was reviewed on a field trip to the Western Isles.
He had remained well with no vomiting illnesses in the intervening period.
Generalised upper and lower limb muscle hypertrophy was more prominent. There
were no fixed deformities and the muscles were not stiff. A toe-to-toe gait was
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evident on running. Surface EMG of the gastrocnemius, extensor digitorum and
frontalis muscles showed continuous generalized myokymic activity.
This boy, who is now 15 years old, has continued under regular review in my clinic.
He has not had another acute episode like the one aged 3 years. He has had no
episodes of ataxia. His muscles are hypertrophied and rhythmic myokymia is
clinically evident on observation of the calfmuscles and fingers (Figure 5.2). He has
a mild degree of tendo-achilles shortening bilaterally but he is able to bring his
ankles to the neutral position. He complains of feeling tired after exercise but does
not suffer from muscle cramps. He has been managed with physiotherapy, ankle foot
orthoses at night and carbamazepine. He has no significant functional deficit due to
his myokymia and I have prevented an orthopaedic surgeon from performing a
tendo-achilles release.
Case II
The 39-year-old father of the proband was first seen on the field trip. He had no
history of episodic ataxia, stiffness, or other muscle symptoms. There were no older
living relatives to ask whether he toe walked as a child and review of general practice
notes revealed no history ofmuscle or postural problems.
The only abnormalities on clinical examination were calfmuscle hypertrophy and
subtle myokymia of his dorsal interossei. Surface EMG revealed myokymia with
continuous motor unit activity within the right lateral gastrocnemius and right
extensor digitorum.
Case 12 and 112
The 35-year-old mother of the proband had a normal neurological examination and
surface EMG study. The 19 month old male sibling of the proband had a normal
neurological examination and surface EMG study.
Case 113
The younger sister of the proband was born after the field trip. She is reviewed
regularly with her brother in my clinic. She presented to her local district general
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hospital aged 2 years unable to walk during a vomiting illness. She had increased
tone in upper and lower limbs with her legs extended. Myokymia was clinically
evident. Her increased tone settled within 24 hours. She had a further episode of
neuromyotonia lasting 24 hours aged 6 years following a general anaesthetic for a
tooth extraction.
Her calf muscles are hypertrophied (Fig 5.2) and she has clinically evident
myokymia. Surface EMG revealed continuous motor unit activity. She complained
of occasional cramp like pain in her calf muscles which has responded to therapy
with carbamazepine.
5.3.2 Genetic and functional studies
Sequence analysis of the KCNA1 gene was performed on DNA from all family
members. A novel heterozygous mutation was identified in the three affected
individuals. It was not present in the two unaffected cases. The point mutation
C731A results in a radical amino acid substitution of praline to histidine at position
244 in the intracellular loop between transmembrane segments 2 and 3 (Figure 5.3).
Mutant cRNA was injected independently into Xenopus oocytes and current
measured across the mutant channel and compared to the wild type channel. There
was no difference in the current amplitude through mutant and wild type channels
(Fig 5.4). When expressed together with wild type channels the current amplitude
was relatively increased relative to wild type alone. Further studies looked at the
activation and de-activation time course of the channel. When expressed on its own,
the voltage activation of the P244H mutant channel was shifted to a more
hyperpolarized potential and deactivation was slowed. These two effects were
abolished by expressing the mutant channel with wild type channels.
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Figure 5.3 Cartoon of Kv1.1 potassium channel subunit showing positions of
various mutations including the P244H mutation in the family with
generalised myokymia.
Figure 5.4. Amplitude histogram of currents through mutated and wild type




This family is the first reported with a genetic basis for isolated neuromyotonia or as
we term it familial generalised myokymia (Eunson et al 2000). This clinical study
expands the phenotypic spectrum associated with mutations in the KCNA1 gene. As
is the case with many genetic channelopathies there is an autoimmune counterpart.
Isaacs syndrome, or acquired neuromyotonia, is associated with autoantibodies
directed against potassium channels in peripheral nerve and myokymia is sometimes
seen in association with Kvl.l antibody related limbic encephalitis (Shillito et al
1995; Vincent et al. 2004).
I believe that the proband in our family had a viral infection associated with vomiting
leading to subtle pH, C02 or electrolyte changes in the area surrounding the cell
membrane therefore aggravating the potassium channel dysfunction. The peripheral
nerve hyperexcitability caused by the mutant channel caused continuous motor unit
action potentials and clinical myokymia. This continuous involuntary muscle
contraction over time leads to muscle hypertrophy. When the channel function was
further compromised in the vomiting illness the continuous motor unit activity was
so prominent that it resulted in neuromyotonia (stiffness), postural abnormalities and
an inability to walk. Deep tendon reflexes were difficult to demonstrate because of
the neuromyotonia. The creatine kinase levels were raised due to the excessive
involuntary muscle activity.
Five families in three publications had been reported with features similar to this
Scottish family (Ashizawa et al. 1983; Auger et al 1984; Jamieson & Katirji 1995).
Ashizawa et al described a family with seven affected individuals. The proband, a
three-year-old girl presented during an upper respiratory tract infection with
diarrhoea in almost exactly the same way as the proband in our family. She was
unable to walk, her legs were stiff and persistently extended, she had continuous
twitching ofmuscles and her creatine kinase was raised. In one of the two families
described by Auger et al in 1983 all three affected individuals (mother and two
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daughters) also had neonatal convulsions. The authors commented that these may
have been muscle contractions resulting from spontaneous muscle activity and
misinterpreted as epileptic events. Dedek et al described a family with benign
familial neonatal convulsions and myokymia associated with a KCNQ2 mutation
(Dedek et al 2001). Therefore KCNQ2 as well as KCNA1 mutations can be
associated with familial generalised myokymia. If benign neonatal convulsions
occur, KCNQ2 would seem a more likely candidate.
The two affected children in this family have been treated with carbamazepine. It is
difficult to know if this is producing a significant clinical benefit however they have
not had any further episodes of severe neuromyotonia and do not suffer any muscle
cramps.
The expression studies on the P244H mutant channel when co-expressed with the
wild type showed it had the smallest effect on K+ currents. It would seem to have
much less significant effects than the mutations reported with EA1 and myokymia or
EA1, myokymia and epilepsy. This may go some way to explaining the milder
phenotype with isolated myokymia. This family may not have presented to
neurology if the proband had not had a significant vomiting illness. The only clinical
sign had been intermittent toe walking. This is a relatively common presentation in
infancy with a variety of causes but mostly unknown.
This study has produced novel insights into the variable phenotypes associated with
KCNA1 mutations and through expression studies has suggested mechanisms at a
cellular level that may influence the clinical phenotype.
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Chapter 6
Episodic Ataxia Type 2 & Epilepsy
6.1 Introduction
In this chapter I describe a single case study of a child with episodic ataxia type 2
(EA2) which has provided early insights into the causes of absence epilepsy in
humans. This individual's clinical features, along with molecular genetic and
expression studies, have been published in The Lancet (Jouvenceau et al 2001).
EA2 is the commonest of the paroxysmal ataxias and is associated with mutations in
the CACNA1A gene which codes for the alpha subunit of a voltage gated P/Q type
calcium channel (Ophoff et al 1996). The channel is made up of one major
transmembrane alpha 1 (ajA) subunit and auxiliary (3, 0128, and y subunits (Catterall
WA 2000b). The alpha subunit is the pore forming part of the channel and is
essential for voltage sensing and is the major determinant of the biophysical
properties of the channel.
EA2 typically presents in autosomal dominant pedigrees. EA2 is allelic with familial
hemiplegic migraine (a variant of migraine with aura) and spinocerebellar ataxia type
6 (a late onset slowly progressive ataxia). These are 3 distinct conditions however
phenotypic overlap may occur (Jen et al 1999). In contrast to EA1 the episodes of
ataxia in EA2 are much longer, lasting hours (Parker 1946; Hill & Shermann 1968;
White 1969; Donat & Auger 1979; Baloh et al. 1997; Jen et al 2007).
Individuals with EA2 can have interictal cerebellar signs and a slowly progressive
background ataxia (Yue et al 1997). Onset of symptoms is typically in childhood.
Triggers for the ataxic episodes include physical and emotional stress. This includes
88
startle, movement and anxiety. Gait ataxia may be accompanied by dysarthria,
nystagmus, vertigo, nausea and headache. Acetazolamide may be dramatically
effective in EA2, so much so that it has been termed acetazolamide responsive ataxia
(Griggs et al 1978). About 50% ofEA2 patients report headache which fulfil the
diagnostic criteria for migraine. The headache can have features of a hemiplegic
migraine.
Gaze evoked nystagmus may be present between attacks but interictal cerebellar
signs may be difficult to demonstrate. Failure to suppress the vestibular-ocular reflex
with fixation may be the only early sign of cerebellar vermis dysfunction. With time
spontaneous vertical nystagmus may appear. MRI may reveal subtle vermian atrophy
and MR spectroscopy can show an alkaline cerebellar pH (Bain et al 1992; Sappey-
Marinier et al. 1999). Channel dysfunction can therefore cause chronic and
progressive symptoms as well as paroxysmal events.
6.2 Methods
6.2.1 Clinical study
The index case was referred to Professor JBP Stephenson in Glasgow for a second
opinion by Dr Venkataswaran Ramesh, Paediatric Neurologist, Newcastle General
Hospital. I undertook the clinical evaluation of the child along with Professor
Stephenson. The clinical examination was videotaped. I arranged for DNA to be
forwarded to colleagues in London and communicated with them regarding the child.
6.2.2 Molecular Genetic and expression studies
The molecular genetic and expression studies were undertaken by Ann Jouvenceau,
Louise Eunson and Alex Spauschus and colleagues in Professor Mike Hanna and
Professor Dimitri Kullman's laboratories in the Institute ofNeurology, Queen
Square, London. DNA from the index case and both his parents was studied.
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Following exon amplification by PCR the CACNA1A gene was sequenced.
Genotyping to test for paternity was performed.
Expression studies of the mutation identified were performed in a Xenopus oocyte
system. The mutant and wild type aiA subunits were co-expressed together or
independently with P and (X28 subunits.
6.3 Results
6.3.1 Clinical details
The index case was 11 years old when seen in Glasgow. He had an uneventful
pregnancy and birth history. His mother was concerned that his development was
slow at around 1 year of age. He walked at around 18 months but was said to fall
frequently and was described as a clumsy child. His first words were at 18 months
however his speech was unclear and he attended speech therapy pre-school. At the
age of three years he developed nocturnal generalised tonic clonic epileptic seizures
(GTCS) and daytime absences. The GTCS stopped at age 8 but the absences
continued. Aged 6 years he had an EEG which showed interictal polyspike and wave
discharges in the resting record and a further burst of generalised spike and wave
during hyperventilation. He was commenced on lamotrigine and subsequently treated
with gabapentin and clonazepam without significant effect on the absences.
From 8 years he developed attacks of unsteadiness of gait, dysarthria and diplopia.
He retained a normal conscious level through these events. The episodes lasted up to
3 hours and had no clear precipitants. These attacks were clearly different from the
absences. The episodes increased in frequency such that on most days he would feel
unsteady for a period particularly in the mornings. He felt exercise made him less
unsteady. He had been examined during an event and had marked gait and upper
limb ataxia with slurred speech and prominent horizontal and vertical nystagmus. He
was appropriately responsive. EEG during the events showed runs of slow wave
activity and sharp waves over one or other hemisphere but no evidence of a non-
convulsive status. Acetazolamide and flunarizine did not reduce the frequency of
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events significantly. An MRI age 11 was reported as normal. He is in mainstream
school with no evidence of a global learning difficulty.
There is no family history of episodic ataxia. He has three siblings who are all well.
The only paroxysmal events in the family are night terrors in a sibling and syncopal
events in his mother.
When he was reviewed in Glasgow he was said to be having a good day. He had a
broad based stance and gait with minimal truncal ataxia. There was no tremor. There
was no evidence of upper limb ataxia with no evidence of dysdiadochokinesia or
dysmetria or on finger nose testing. Cranial nerve examination apart from eye
movements was normal. He had a gaze evoked nystagmus with both right and left
horizontal eye movements. He also had a gaze evoked vertical nystagmus. The other
feature ofnote was failure to suppress his vestibular-ocular reflex with fixation. All
aspects of the examination were captured on videotape.
Given the history of episodic ataxia and the findings on clinical examination we felt
that a possible diagnosis, despite lack of response to acetazolamide, was episodic
ataxia type 2 with absence epilepsy. As there was no family history this would most
likely be associated with a de novo mutation in CACNA1A. In view ofmy
collaborations with colleagues in the Institute ofNeurology on cases with EA1 and
epilepsy I communicated with them directly and they agreed to sequence the
CACNA1A gene.
6.3.2 Molecular Genetic and expression studies
Colleagues at the Institute ofNeurology identified a heterozygous point mutation
(C5733T) in CACNA1A in the index patient. The mutation results in an arginine
(CGA) to stop (TGA) change at amino acid position 1820 (Fig 8.1). The mutation
was not present in either of his parents or in 200 control chromosomes. Genotyping
suggested a less than one in a million chance of non-paternity. This confirmed the
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clinical assessment that this was a de novo mutation. The R1820stop mutation is the
most distal truncating mutation identified in the gene to date.
When the mutant channel was expressed in Xenopus oocytes the currents measured
were indistinguishable from those across un-injected oocytes. This indicates that the
mutant channel was non-functional. When the R1820stop mutant channels were
injected along with wild type channels the current measured was significantly
reduced compared to wild type alone. The mutant channels demonstrated a dominant
negative effect on the wild type channels.
6.4 Discussion
This was the first report linking a calcium ion channel subunit to absence epilepsy in
humans. There are several pieces of evidence that suggest the mutation identified in
the index case was pathogenic. The phenotype of the index case with episodic ataxia,
with interictal cerebellar signs was consistent with EA2. The mutation was
heterozygous as seen in other cases ofEA2. The mutation was not detected in control
chromosomes or unaffected family members. The mutation was a premature stop
codon at the beginning of the highly conserved C terminus. The expression studies
indicated that the function of the channel was significantly impaired by the mutation.
Epilepsy is not typically a feature ofEA2 but EEG abnormalities including focal
slow wave activity, sharp waves and spike and wave complexes have been reported
in interictal EEG studies (Van Bogaert and Szliwowski 1996). The R1820stop
mutation produces a more severe impairment in channel function than demonstrated
in functional studies of other CACNA1A mutations associated with EA2. This may
explain the absence epilepsy in this child.
Several spontaneous and mutagen induced mouse strains exist with mutations in the
homologous murine CACNA1A gene (Fletcher & Frankel 1999). These include the
tottering, leaner and rolling. The tottering mouse is remarkable in that it exhibits
ataxia, and intermittent dystonia as well as absence epilepsy (Noebels & Sidman
92
Figure6.1Cartoonofvoltageatedca ciumhannel1subu itow ngp sitio sm tati nass c at dw hEA2.T r showsthepositionfmutationdetec edinchilw hEA2anb nceep l psy(T kfr mJouve c autl2001) CIt6l)Cl«CCtCHCCVOAOM 1CtC Mf
1979). The leaner subtype of the homozygous tottering mouse has progressive
ataxia, cerebellar degeneration and epileptic absences with spike wave discharges on
EEG. These mice strains are regarded as very important models for studying the
physiology of generalised epilepsies with generalised spike and wave discharges -
the common idiopathic generalised epilepsies. Oscillations within the thalamocortical
loop are thought to be important in generating spike wave discharges in absence
epilepsy. There is evidence of abnormal control of thalamocortical activity in the
tottering mouse (Caddick et al 1999). The index case in this report therefore
supports the proposition that P/Q type calcium channels are important in the
generation of generalised epileptic seizures in humans.
Since the index case and genetic study were published in the Lancet further evidence
has emerged linking dysfunction of the CACNA1A channel and absence epilepsy. A
spontaneously occurring rat strain called groggy, which has ataxia and absence
epilepsy has been found to have mutations in the ciia subunit of the calcium channel
(Tokuda et al 2007).
Further families with absence epilepsy, episodic ataxia type and CACNA1A
mutations have been reported (Imbrici et al 2004; Jen et al 2004). In one family five
individuals had generalised 3Hz spike and wave on EEG, absence epilepsy and
ataxia (Imbrici et al 2004). One family member with absences developed marked
cerebellar ataxia only when he was on anti-epileptic medication. This suggests that
the mutation causing the epilepsy can also make an individual vulnerable to the side
effects ofmedication and determine the nature of the side effect, in this case ataxia.
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Chapter 7
Benign Familial Neonatal Seizures
7.1 Introduction
The syndrome of benign familial neonatal seizures (BFNS), which is also termed
benign familial neonatal convulsions, was the second idiopathic epilepsy syndrome
(after autosomal dominant nocturnal frontal lobe epilepsy) with a defined genetic
basis. In this chapter I describe the clinical evaluation of two large Scottish families
with BFNS. These studies expand the genetic and clinical spectrum of this disorder.
The molecular genetic study of family A has been published (Heron et al 2007).
BFNS is an uncommon disorder but probably unrecognised in many families. In the
course ofmy clinical practice I have diagnosed two further families with BFNS who
are discussed briefly. Several individuals from both families reported in this chapter
have presented with neonatal seizures to the neuroscience service at RHSC, Glasgow
over the last 30 years.
BFNS is an autosomal dominant disorder characterised by the onset, in the first week
of life, of epileptic seizures, in otherwise well neonates (Rett & Teubel 1964; Ronen
et al 1993). The seizures are typically tonic at onset, with cessation ofmovement,
ocular deviation, sometimes apnoea and autonomic symptoms, with progression at
times, to clonic features. The seizures usually cease spontaneously between a week
and four months after onset. Some individuals may only have one or two days of
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seizures. Previous studies have suggested a 5-15% risk of epileptic seizures later in
life. The majority of affected individuals have no cognitive problems.
This was the first idiopathic genetic epilepsy on which successful linkage was
reported, to chromosome 20ql3.2 in 1989, and 8q in 1993 (Leppert et al 1989; Lewis
et al 1993). BNFS is associated with mutations in two potassium channel subunit
genes KCNQ2 (Chr 20) and KCNQ3 (Chr 8) (Biervert et al 1998; Singh et al 1998;
Charlier et al 1998). KCNQ2 and KCNQ3 code for the Kv7.2 and Kv7.3 channel
subunits respectively. These two channel subunits are involved in the structure of the
M-channel which allows flow of the M current (Wang et al. 1998). The M current is
a slowly activating and deactivating potassium current that plays a critical role in
determining the electrical excitability of neurons. It is reasonable to expect that its
dysfunction may lead to epileptic seizures.
Infants born prematurely will have their seizure onset around their due date. Why the
seizures occur at such an age specific period is unknown but is likely to be due to
developmental gene expression of the gene itselfor modifying genes. A recent study
has suggested an increase in KCNQ2 and KCNQ2 gene expression in several brain
regions including hippocampus in late fetal life and a decrease after birth (Takaumi
et al 2008). Several families have been reported worldwide with mutations in
KCNQ2 and KCNQ3. The vast majority >90% have mutations in KCNQ2 (Singh et
al. 2003, Steinlein et al 2007).
7.2 Methods
7.2.1 Clinical studies
The probands from both families were referred to the Royal Hospital for Sick
Children with onset of seizures in the neonatal period. The families were assessed as
detailed in the methods section. The key part of the evaluation was the family
history. In family A, case 11:5, the grandmother of the proband provided the
extensive family history. Several of her children were clinically affected. A
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videotaped description of the family history was taken. Interictal EEG was available
for several cases. Video telemetry captured seizures in one patient.
7.2.2 Molecular genetic study
DNA samples from the probands and close affected relatives were forwarded to John
Mulley's laboratory at the Women and Children's Hospital, Adelaide. Sarah Heron,
Kathleen Cox and Bronwyn Grinton undertook the molecular genetic work. The
probands were tested by direct sequencing for mutations in all coding exons of
KCNQ2 and exons 5 and 6 ofKCNQ3. DNA from family A was subjected to
multiplex ligation probe analysis (MLPA) to look for deletions and duplications
which would not be detected by sequencing. This is a recently developed DNA
dosage technique which can look at copy number variations in the genome and is
therefore able to detect deletions or duplications within a specific region. With
informed consent DNA was tested in 4 affected members of family A. In family B
DNA was available in two affected individuals and two obligate carriers.
7.3 Results
7.3.1 Clinical Study of family A
The pedigree of family A is detailed in figure 7.1. The pedigree showed that the
benign familial neonatal seizures were inherited in an autosomal dominant fashion.
21 individuals from a kindred comprising 75 individuals had a history of neonatal
(19) or infantile onset (2) seizures. 7 individuals had neonatal onset and offset of
their seizures. 6 cases had neonatal onset and offset in the first 6 months of life. 6
cases had onset of their seizures in the neonatal period with further seizures into
childhood in four cases and into adult life in another 2 cases. 2 had onset outside the
neonatal period and 1 of these cases has had seizures continuing into adult life. Both
individuals with onset in infancy were interviewed and DNA was available for
testing.
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7/21 (33%) of individuals had seizures outside of infancy with three persisting into
adult life. None of the affected individuals had learning disability.
Illustrative Case Histories
Case IV: 15
The proband presented on day 5 with a cluster of epileptic seizures. In between
seizures her behaviour was normal as was the neurological examination. She became
stiff, apnoeic and blue with a few clonic jerks of limbs. The episodes lasted 90
seconds to 3 minutes. She had a single dose of phenobarbitone but the seizures
continued on day 6 and carbamazepine commenced. At 4 weeks carbamazepine was
stopped due to a rash. She didn't take regular medication after this. Up to 4 months
she had four brief clusters of seizures each lasting a minute. Following this she had
clusters of brief seizures when she was unwell with viral infections once or twice a
year up until 4 years of age. In the seizures outside of infancy she goes stiff, and has
clonic movements of face, upper and lower limbs lasting 1-2 minutes. Her
development is normal. Interictal EEG was normal.
Case 111:17
The mother of the proband had a single generalised convulsion during a febrile
illness aged 10 months. Her mother said she had an abscess in her groin at the time.
Her development is normal.
Case 111:12
The aunt of the proband had no neonatal seizures. Her events started at 4 months
within 24h of diphtheria, tetanus and pertussis (DPT) immunisation. She was
admitted to hospital with a cluster of frequent seizures, every hour or two, over 2-3
days. She was commenced on phenobarbitone. The seizures were described as
generalised clonic lasting 1-2 minutes. She had no further events until her teenage
years. She had a cluster of 3 focal seizures with secondary generalisation in 24h at
the age of 16. She described a tingling feeling in arm and jaw which then evolved
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into a secondary generalised clonic seizure. She had two events in her first pregnancy
aged 20y. At 35y and 40y she had similar clusters in a 24h period. She is currently
taking oxcarbazepine. Interictal EEG was normal.
Case II.9
Events started as neonate within first few days of life. Convulsions described as
generalised. Occasional seizures throughout childhood. Treated with phenobarbitone
until 16 years of age. Has had one or two epileptic seizures as an adult but no longer
on medication.
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Figure 7.1 Pedigree ofFamily A
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7.3.2 Clinical Study of family B
The pedigree of family B is shown in figure 7.2. The pedigree demonstrates
autosomal dominant inheritance of the neonatal seizures. The kindred has 37
individuals with 10 affected by neonatal seizures. No individuals had onset of
seizures outside the neonatal period. None of the cases had seizures beyond 3
months of age. None of the affected individuals have learning disability.
Illustrative case histories
Case IV6 - Proband
The proband presented aged 4 days with clusters of seizures. She had several
seizures per day. CT brain scan was normal. Interictal EEG was normal. Video-EEG
captured two epileptic seizures. The first episode was accompanied by sharp and
slow wave complexes over the left hemisphere, spreading to involve the right
hemisphere (Figure 7.3). The second episode had onset over the right hemisphere
with sharp and slow waves restricted to the right hemisphere. In between the seizures
she fed well and behaved normally with a normal neurological examination. She was
commenced on carbamazepine. She had no further seizures after the neonatal period.
Age 11 her development is normal.
Case IV:5
The father of the proband had no history of neonatal seizures or any other
neurological problems.
Case IV:7
The aunt of the proband had seizures with onset and offset in the neonatal period.
She had further seizures in infancy, childhood or adult life.
Case V:1
The granddaughter of case IV:7 had four seizures in total the first on day 2 of life
and the last on day 4. In the events she stared forward and then had twitching of the
left side of her body for 10-30 seconds. In between the events her behaviour, feeding
101
and neurological examination was normal. She had a single dose of phenobarbitone.
She had a lumbar puncture, MRI of brain and interictal EEG which were all normal.
She has had no further events and has normal development. Her father, the son of
case IV:7, had no neonatal seizures or other neurological problems.
Case IV:3
Onset of seizures was day 2 with offset at 3 months. In total she had 8 or 9 events.
She became rigid, neck was extended, her eyes rolled back and the whole event
lasted about 3 minutes. Interictal EEG was normal. Development has been normal
with no seizures throughout childhood and adult life to the age of 30.
7.3.3 Molecular genetic study
Family A
DNA was available from 4 affected family members. Sequencing of KCNQ2 and
KCNQ3 detected no coding or splice site mutations. MLPA was used to test for copy
numbers of each exon ofKCNQ2. MLPA detected a duplication of exons 3-12 in all
affected individuals tested.
Family B
DNA was available from the probands father (111:5), the probands aunt and her
cousin the father of case V:l. Sequencing ofKCNQ3 in all individuals tested
revealed a mutation in exon 6 of the gene, c,1019G>T (p.G340V).
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Figure 7.3
7 channel MedHog EEG recording of proband from family B showing focal
onset of epileptic seizure with spike and slow wave abnormalities developing
over the left hemisphere and spreading to the right. A concomitant video
recording showed an epileptic seizure as described in the text.
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7.4 Discussion
Family A and family B both have clinical features in keeping with benign familial
neonatal seizures however there were several important differences between the two
families illustrating variable presentation in the syndrome and suggesting that the
different genetic aetiologies influenced the phenotype. 10/10 individuals in family B
had onset of seizures in the neonatal period, as did 19/21 individuals in family A.
The pedigrees indicated an autosomal dominant pattern of inheritance in both
families. All individuals had a normal developmental outcome.
The family history was the key to making the diagnosis however it was notable that
either due to variable penetrance (family B), or a lack of family knowledge about the
history, obtaining a history ofneonatal seizures, even in families with so many
affected, was not always straightforward.
The major difference in the two families was that in family A one of the oldest living
female relatives, the grandmother of the proband, had a clear overview of the family
history. This individual had 2 younger siblings, 2 children, 7 nieces and nephews,
and 5 grandchildren with seizures. The oldest living female relative is usually the
most important person to speak to in the early stages of constructing a pedigree and
family history. In family B two individuals presented in the 1970s to my supervisor
Professor John Stephenson. He was aware of the family history of neonatal seizures
and normal development and diagnosed benign familial neonatal seizures. In an EEG
report on case IV: 1 he commented, "this family should bepublishedMore than 30
years later the paper is being written.
As is the case in these families they will continue to present to medical services
every generation. In the late 1990s the proband presented. There was a vague history
at the time of neonatal seizures in an aunt. The more extensive family history was
unearthed by direct questioning and cross referencing to a diagnostic coding system
established in the neurosciences unit in the 1970s. DNA was taken from the
proband's father who would have been an obligate carrier of the genetic mutation.
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The mutation in KCNQ3 was identified several years later. By this time the family
were no longer under follow up. They had moved house and the GP and local health
board had no record ofwhere they had gone to. I was making further efforts to trace
them when case IV: 10 presented to another hospital in the Glasgow area with
neonatal seizures. Her case was mentioned to me by a colleague at a coffee break in
an academic meeting with, again, a mention of a vague family history of neonatal
seizures. I arranged to see the family in clinic and was able to establish a link to the
proband's family. This allowed me to contact the proband's father and inform him
and the rest of the family of the genetic diagnosis. The re-presentation of the family
every few years with another neonate going through extensive and at times invasive
investigations is typical ofBFNS. Knowledge of the genetic defect in family B
would probably save neonates extensive investigations and prolonged treatment with
anti-epileptic medication as all family members to date stop having seizures in the
neonatal period.
The presentation of two cases from family A with their first seizures later in infancy
demonstrates that there can be some overlap between BFNS and two other benign
epilepsy syndromes, benign familial neonatal infantile seizures (BFNIS) and benign
familial infantile convulsions (BFIC). BFNIS is associated with missense mutations
in a sodium ion channel gene SCN2A (Heron et al 2002, Herlenius et al 2007). BFIC
has been linked to chromosome 16 but no gene has been identified (Caraballo et al
2001). The mean age of onset of seizures in BFNIS is 11 weeks (range 2d - 6m)
against 2-3 days in BFNS (range ld-6m) and 6 months (range 2-20m) in BFIC. This
demonstrates that the diagnosis of a family should be based on the age at
presentation of the majority of the individuals. In small families or isolated cases it
would be justified to test KCNQ2, KCNQ3 and SCN2A.
It is of note that there was a variable outcome in the two individuals with onset of
seizures outside the neonatal period. The mother of the proband had a single seizure
in the context of an intercurrent illness. Her sister had her first seizure within 24h of
her first DTP immunisation. This further emphasises the point that seizures in
proximity to this immunisation are more likely to be genetic in nature rather than a
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specific consequence of the immunisation (Berkovic et al 2006). This individual has
had infrequent clusters of focal seizures throughout her life suggesting that the
KCNQ2 mutation alters neuronal excitability to a degree that is only significant
given certain environmental circumstances. It is likely that other genetic factors
determine the significant difference in seizure frequency between close relatives.
33% (7/21) of individuals in the family had seizures outside the neonatal and
infantile period. This is a much higher percentage than reported in other BFNS
families. As this the first family reported in the literature with a KCNQ2 duplication
it remains to be seen whether other families with similar genotypes have such a high
incidence of epilepsy later in life. It seems that the risk of seizures in older
individuals is related to the specific mutation found in each family. Case 111:12 had
seizures as an adult with tingling in her mouth at onset. This has a similarity to the
focal seizures seen in benign rolandic epilepsy (benign childhood epilepsy with
centrotemporal spikes- BCECTS). In Rett and TeubeTs original family with BFNS, 2
of nine affected neonates had seizures with semiology suggestive ofBCECTS (Rett
and Teubel 1964). This family has been re-evaluated and found to have a KCNQ2
mutation (Zimprich et al 2006). The same mutation has been found in another family
with BFNS who had one individual with centrotemporal spikes at 3 years (Coppola
et al 2003). A Japanese BFNS family had two affected children with centrotemporal
spikes and rolandic or sylvian seizures to the age of 9 years (Maihara et al 1999).
Benign rolandic epilepsy (BRE) is the commonest idiopathic focal epilepsy of
childhood. The importance of KCNQ2 mutations or variants in BRE is yet to be
clarified though one preliminary study found only one functionally significant
mutation in 53 pedigrees with BRE (Neubauer et al 2008).
In all of the four KCNQ3 families reported previously only two of the individuals
had seizures reported beyond the neonatal period (Charlier et al 1998, Hirose et al
2000, Singh et al 2003, Li et al 2007). These were the proband his sister from Hirose
et al. who had seizures at 6 months and three years. Family B is the fifth family
reported with a KCNQ3 mutation and has a similar relatively mild and benign
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phenotype. The finding of a KCNQ3 mutation should therefore confer a relatively
good prognosis.
2 individuals have been reported with refractory neonatal seizures an epileptic
encephalopathy and KCNQ2 mutations. One child had refractory seizures to 15
months which are now controlled, but has severe learning disability aged 4 years.
This child had a de novo KCNQ2 mutation (Schmitt et al 2005). One familial case
had refractory seizures to 13 weeks, which are now controlled, but she is left with
developmental delay at two years. This child had a familial KCNQ2 mutation.
(Dedek et al 2003). Steinlein et al. reported that in 4 out of 10 BFNC families with
KCNQ2 mutations in which follow up was available, each family had one individual
with significant developmental problems (Steinlein et al 2007). The condition when
associated with a KCNQ2 mutation may not be as benign as previously thought. A
KCNQ2 mutation in the voltage sensor region has been associated with BFNS and
myokymia in one family (Dedek et al 2001). There is emerging evidence that
KCNQ3 mutations are associated with "pure" BFNS whereas KCNQ2 mutations are
associated with BFNS "plus" other features. KCNQ2 mutations are about ten times
more frequent than KCNQ3 mutations. I have identified two further small families
with BFNS who have KCNQ2 mutations identified within John Mulley's lab (Figure
7.4a and b).
KCNQ2 and KCNQ3 can exist as homomeric potassium ion channels but the typical
M channels are heteromeric, tetrameric channels with a mixture ofKCNQ2 and
KCNQ3 subunits. The M current is thought to be important in controlling the resting
potential ofmany neurons and limits repetitive firing. When functional studies are
performed mutant channels need to be expressed alongside wild type channel
subunits of the same and different types. When KCNQ2 mutants are studied on their
own there is a significant reduction in current compared to wild type. When the
mutant channel subunit is expressed with wild type KCNQ2 and KCNQ3 subunits
the reduction in current is much smaller. It may be that this relatively modest
reduction in current is only significant in the majority of individuals in the neonatal
period. This may be related to the developmental expression of these channels
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around term or it may be that the switch from GABA acting as an excitatory
neurotransmitter to it acting as an inhibitory neurotransmitter lessens the
physiological impact of the KCNQ2 and KCNQ3 mutations ( Kanaumi et al 2008 ;
Reid et al. 2009).
As loss of function mutations seem to underlie BFNS, medications that stabilise the
M current and open the M channel could therefore be candidates as anti-epileptic
medications. The compound retigabine acts by opening M channels and is currently
undergoing clinical trials as an anti-epileptic medication (Conte Camerino et al
2007). Retigabine acts on all the KCNQ subunits except for KCNQ1 which is a
cardiac and not a neuronal channel subunit.
The study of families A and B emphasises the variability in phenotype and genotype
in BFNS. Family A would not have had a genetic diagnosis without the use of the
relatively new technique MLPA. Using this technique our collaborators in Australia
also detected KCNQ2 exon deletions in 3 families who were negative for KCNQ2,
KCNQ3 and SCN2A mutations on sequencing (Heron et al 2007). Family A remains
the only one reported worldwide with a KCNQ2 exon duplication. This report
emphasises the importance of a two tier strategy in testing families with BFNS with
the use ofMLPA in sequencing negative cases.
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Nocturnal Frontal Lobe Epilepsy
8.1 Introduction
In this chapter I report the clinical study of two large Scottish families with an
uncommon genetic epilepsy called autosomal dominant nocturnal frontal lobe
epilepsy (ADNFLE). The two families "D" and "S" have featured in four
publications which I will refer to in the chapter. Family D was the third reported
worldwide with a mutation in the gene for the neuronal nicotinic acetylcholine
receptor a4 subunit (CHRNA4) and family S was one of the first two families
reported worldwide with a mutation in the neuronal nicotinic acetylcholine receptor
P2 subunit. The principal neuronal nicotinic acetylcholine receptor in the brain is
made up of 5 subunits, 3 p2 subunits and two a4 subunits, which assemble together
to form the ionic pore (Bertrand D, 2002). The clinical study of family D emphasises
the major consequences that incorrectly phenotyping even one individual in a family
can have on molecular genetic studies. The study of families D and S was the first in
which families with a single epilepsy syndrome (ADNFLE), caused by mutations in
different genes, had their phenotypes compared (McLellan et al. 2003)
ADNFLE is a familial partial epilepsy syndrome characterised by clusters of frontal
lobe motor seizures in sleep (Scheffer et al. 1994; Scheffer et al. 1995). ADNFLE
was the first idiopathic epilepsy to have a defined genetic cause with a Ser248Phe
mutation in the CHRNA4 gene identified in a large Australian kindred. CHRNA4
codes for a subunit of a ligand gated ion channel. The clinical study of a family
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comprising 25 affected individuals by Ingrid Scheffer allowed linkage to
chromosome 20 and the subsequent discovery of the CHRNA4 mutation through
work done by teams led by John Mulley and Ortrud Steinlein (Scheffer et al. 1995;
Steinlein et al. 1995). Subsequently different CHRNA4 mutations were detected in a
Norwegian family and a Spanish family with ADNFLE (Steinlein et al. 1997; Saenz
et al. 1999).
The clinical syndrome ofADNFLE is distinctive but there is considerable variability
in severity between families and between individuals within families. In the seminal
paper by Scheffer et al. five families from Australia, Britain and Canada are
described with 47 affected individuals (Scheffer et al. 1995). Many affected
individuals had been misdiagnosed as parasomnias, pseudo-seizures or nocturnal
paroxysmal dystonia. The key features of the syndrome as described in 1995 were
the childhood onset of clusters of partial seizures in sleep that persist into adult life.
At seizure onset there was often a vocalisation and a non-specific aura, sometimes
including a sensation of breathlessness. Consciousness was retained by several
individuals with some having a sensation of fear. A tonic stiffening of the body
sometimes with dystonia of a limb could be followed by hyperkinetic features with
clonic jerking of limbs. The neurological examination was normal, cognitive abilities
were normal, neuroimaging was normal, interictal EEG was normal and ictal EEG
often showed no surface abnormalities. The recognition of the family history was




Two families, originally from central Scotland, were identified and their pedigrees
established (Figures 8.1 & 8.2). All living affected individuals underwent clinical
evaluation comprising personal or telephone interview, clinical examination and
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medical records review as detailed in Chapter 5. Both these families are very large
and have had clinical evaluations in several centres.
8.2.1a Family D
The proband from family D (case IV7) was referred to Professor John Stephenson's
clinic in Glasgow. The diagnosis ofADNFLE was made by him. The initial
evaluation of the family was undertaken by John Stephenson and John Tolmie
(Clinical Geneticist, RHSC, Glasgow) in collaboration with Professor Sam Berkovic
in Melbourne. I followed case IV in clinic and undertook the clinical evaluation of
other family members. Two brothers from family D (cases IV1 and IV2) were
independently referred to my clinic for evaluation of paroxysmal events. I arranged
molecular genetic testing on them in collaboration with Professor Sam Berkovic
(Neurologist) in Melbourne and Dr John Mulley (Molecular Geneticist) in Adelaide.
I re-evaluated the clinical histories in family D and interviewed the affected family
members. The proband from family D had several video-EEG studies performed in
Glasgow as well as home videotape of events. EEG studies and home videotape was
available for several other family members as detailed in the results.
8.2.1b Family S
The proband from family S case was referred to Dr Martin Kirkpatrick, Paediatric
Neurologist, Ninwewells Elospital, Dundee for evaluation of nocturnal events. Dr
Kirkpatrick brought a video-EEG of the child and details of the family history for
discussion with Professor Stephenson. I reviewed the case with Professor John
Stephenson and we felt the diagnosis was ADNFLE. I travelled to Dundee and saw
the family and reviewed case records. I contacted colleagues in Australia who agreed
to study DNA from the family. DNA collection in Dundee was supervised by Dr
David Goudie (Consultant Clinical Geneticist). The family subsequently attended my
clinic in Glasgow for a further opinion. I supervised the paper on the phenotypic
comparison of the two ADNFLE families and wrote it with Dr Ailsa McLellan,
Specialist Registrar in Paediatric Neurology, Dundee. Dr McLellan and I made
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Figure 8.2 Pedigree offamily S with ADNFLE
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contact with members of family D and S requesting further clinical information
during the preparation of this paper. One branch of family S live in Sheffield. They
have been seen by Dr Chris Rittey, Paediatric Neurologist, who forwarded clinical
information to me and DNA to Australia.
8.2.2 Molecular Genetic and expression studies
8.2.2a Family D
Linkage and subsequent sequencing studies ofCHRNA4 were undertaken In Dr John
Mulley's laboratory at the Women & Children's Hospital, Adelaide, Australia. Dr
Daniel Bertrand, University of Geneva performed expression studies on the mutation
identified in a Xenopus oocyte model. DNA was available on 11 individuals, 6
affected, 1 obligate carrier and 4 unaffected.
8.2.2b Family S
Sequencing studies ofCHRNA4 and CHRNB2 were performed on 8 individuals in
this family, 6 affected, one obligate carrier and one unaffected by Dr John Mulley's
team in Adelaide. The M2 domains of the two receptor subunits were sequenced as
they form the wall of the ion channel and All previous mutations in ADNFLE had
been found in this region of the a4 subunit. Expression studies of the mutation
identified were performed by Dr Daniel Bertrand in Xenopus oocytes.
8.3 Results
8.3.1 Clinical study
The clinical details for families D and S are summarised in tables 8.1, 8.2, 8.3 and
8.4.
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8.3.1a Family D clinical study & initial molecular genetic data
Illustrative case studies
Case IV:7 (Proband)
The 21 year old proband (IV:7) presented to the neurology service aged 8 years. His
seizures started aged 4 and arose from sleep both at night and during daytime naps. A
video camera and tripod was lent to the family from the neurology clinic. Typically
he would sit bolt upright in bed and his left arm and hand would twist into what was
described as a "flamingo" posture for several seconds, shown clearly in videotape
recordings taken in the home. After the dystonic limb movements had ceased he
would have rhythmic kicking movements of his lower limbs and grasp at the
bedclothes with both hands. He would scream loudly as if frightened, occasionally
calling for his father. Rarely the seizure generalised. Each individual episode lasted
from a few seconds to half a minute but he could have multiple episodes a night
sometimes only separated by 15 minutes. Neurological examination was normal. A
clinical diagnosis of a right mesial frontal lobe epilepsy was made after referral to
neurology and viewing of the home videotape. He had previously been diagnosed by
a paediatrician as having night terrors. Interictal EEG was normal. Video-EEG
telemetry shows stereotyped events but no surface EEG changes are evident. MRI of
the brain was normal. For two years he responded well to carbamazepine but
subsequently his seizures have been poorly controlled on various antiepileptic
medications. The diagnosis ofADNFLE was made after recognition of the family
history.
Case 111:10
The 50 year old, mother of the proband recalls having recurrent episodes from sleep
when she would wake and was aware of a sense of fear during childhood. She
described a funny feeling in her left arm, turning on to her left side and curling up
with trunk flexion for up to a minute. She remembered having to sleep in her parents'
bed even into teenage years. As an adult she continues to have brief recurrent
arousals at night time ofwhich she is not aware.
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Case 111:11
The 47 year old, aunt of the proband has had nocturnal seizures since aged 8 years.
The episodes last only a few seconds and involve her rousing from her sleep, sitting
up and raising her right arm above her head. She is fully aware during a seizure.
Sometimes she will bite down on the blanket. They continue to occur on most nights
between one to three times despite carbamazepine and lamotrigine therapy. This is
much less frequent than during her childhood. They typically occur in the hour
before waking and she may have them if she has a daytime nap.
Case IV:9
This 14 year old boy, a cousin of the proband, presented aged 6 years with a two year
history of episodes of arousal between one or rarely two times in a night, about once
a week. His mother would go through to find him sometimes quietly crying, other
times in an agitated state, looking frightened. He did not appear to recognise his
mother. Sometimes he would talk unintelligibly. There were no abnormal motor
postures during these episodes. There were no other abnormal motor features during
these episodes. They lasted two to five minutes and occurred about two hours into
sleep. At the end of the episode he would fall back into sleep. He has no recollection
of any of the events. They now occur about once every two weeks. At the age of 14
years he still has one or two episodes per month which his mother feels happen more
frequently when he has a "cold". She describes him as looking terrified and "jumping
about the room" not recognising her. He will occasionally sleepwalk and perform
automatic behaviours. Recently he walked into his sisters room picked up her duvet
and folded it neatly at the foot ofher bed before walking back to his room to sleep.
He was initially diagnosed as having ADNFLE. However when I reviewed the full
history with his mother it was clear that he is having parasomnias which can be
clinically classified as partial arousals arising from non REM sleep, mostly night
terrors or somnambulism. He was not commenced on medication.
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Initial Molecular Genetic Studies
DNA samples were taken from affected and unaffected members from family D.
Molecular genetic studies were performed in Adelaide. Case IV9 was initially
misclassified as having ADNFLE and he was screened for the two known mutations
in CHRNA4 on chromosome 20 and for novel mutations in the gene. The proband
did not have CHRNA4 sequencing at this stage. Linkage studies showed that
individual IV:9 and the proband inherited different copies ofCHRNA4. This was felt
to give further evidence that this locus was not involved in the Scottish family.
Studies also appeared to show weak linkage to chromosome 15.
Identification of Cases IV: 1 and IV:2
Case IV: 2
This nineteen year old boy presented at the age of thirteen with a recent onset of
nocturnal events. He had no past history of note apart from a 1-2 minute generalised
clonic seizure associated with a febrile illness aged 2 years. Initially the nocturnal
events occurred only once per night. He would sit bolt upright from sleep, would
stare forwards and was described as having irregular flapping movements of his
arms. He would seem to be intermittently responsive and the episode could go on for
several minutes. He had no recollection of them in the morning.
The mother of cases IV: 1 and IV:2 would have arousals from sleep and if she was in
the dark would get a sensation that "everything was moving fast". She would then
get up and walk as she felt this took away the unpleasant sensation. She retained a
memory of these events. These may be partial arousals from non REM sleep with
preserved memory. On one occasion aged ten she walked into the street. She always
sleeps with the light on. The maternal grandmother of case IV:2 had sleepwalking as
a child.
Based on the history obtained case IV:2 was initially given a diagnosis of a
parasomnia - a non REM partial arousal disorder.
A month after presentation he began to have up to three episodes a night and
therefore the family were lent a video camera from the hospital. The video recording
shows him suddenly sitting upright and then he has slow upper limb jerks for a few
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seconds. This is followed by a period of confused, agitated, hyperactivity including
irregular flapping of his arms and a fall from the bed. The episode lasted several
minutes during which he was able to do things in a semi-directed fashion such as
move objects around his room. He has no recollection at all of any of his seizures. A
diagnosis of frontal lobe epilepsy was made, and after questioning, a link to family D
was revealed through the estranged father of the child.
Events in this individual have been controlled well by carbamazepine therapy
however they do recur when he is up late at night, has drunk alcohol, or is under
emotional stress.
Case IV: 1
The 22 year old brother of case IV:2 presented aged 15 with nocturnal episodes
occurring 3-6 times per night in which he would sit bolt upright, drum his arms legs
irregularly on the bed. This lasts a few seconds, he then becomes aware that he is
awake and has an unpleasant sensation of difficulty breathing which lasts several
seconds. Often he will get up to put a fan on. He would have similar events in
daytime naps. When he was first seen by a paediatrician these events were thought
not to be epileptic however following the diagnosis of his brother's events this boy
was reviewed in the neurology service and a diagnosis ofADNFLE was made. His
events were controlled by slow release carbamazepine at night.
The events are now relatively infrequent and he takes a night time dose of
carbamazepine only at times when he thinks seizures are likely to be more frequent
such as around exam time.
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111:3 F 50 13 3 months None Phenobarbitone




111:7 F 43 8 1 None Phenobarbitone
Carbamazepine
IV: 1 M 19 15 2 None Carbamazepine
IV:2 M 16 14 6 months None Carbamazepine













111:3 Arousal, aware, sensation left arm,










111:7 Sudden awakening, aware, bites blanket, tonic




IV: 1 Arousal, drums arms, looks awake, gets up, turns on
fan, amnesic to event. Up to 6 / night. More if anxious
Improved Interictal
normal
IV:2 Arousal, slow rhythmic upper limb jerking, agitated,
amnesic to event. Home video.
Improved Interictal
normal
IV:7 Sudden awakening, screams, thrashing limbs, falls out
of bed, heavy breathing, aware. 30+/ night at times.
























11:1 F 82 18 9 None Phenytoin
Phenobarbitone
Valproate




111:7 M 42 9 2 None Phenytoin
IV: 1 F 31 17 13 Low mood None









IV:7 F 30 10 2 months Depression Phenobarbitone
Carbamazepine




IV: 10 M 15 9 1 month None Vigabatrin
Lamotrigine







Table 8.3 Family S - clinical features.
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11:1 Sudden awakening, tenses up,
cries, heavy breathing, remains
aware. < 1 minute.
Improved Interictal
normal
11:7 Sudden awakening, curls up,,




111:7 Curls up, heavy breathing,






IV: 1 Not aware, stiffens body, holds






IV:2 Sudden awakening, cries, aware,




IV:5 Violent thrashing of limbs,












IV:9 Dystonic posture upper limbs,
bilateral jerking limbs. Aware,







IV: 10 Groans, tonic extension limbs,





frontal slow. Ictal -
muscle artefact
V:1 Sudden awakening, difficulty
breathing, cries. Tonic extension
left arm. Truncal flexion. <3









Case V: 1 (Proband)
This girl with no learning disability presented age 11 with nocturnal events. She
woke from sleep with a sensation of difficulty breathing. After a few seconds she
would appear to hold her breath and grunt. Sometimes she would recover quickly
and cry or scream. On other occasions she had tonic extension ofher left arm with
flexion of her trunk. Seizures could last from a few seconds to a few minutes.
Stereotyped attacks could occur every 15 minutes through the night. She had clear
recollection ofher events. Seizures also occurred in daytime naps. Video-EEG
captured several clinical events but EEG showed only muscle artefact. Seizures were
initially well controlled on carbamazepine however relapse occurred and further
control was difficult. She became seizure free on a combination of topirimate and
phenytoin.
Case IV: 10
His first events occurred aged 6 when he had recurrent arousals at night with tonic
stiffening of upper limbs with extension lasting a few seconds followed by clonic
movements of all limbs for up to a minute. He could have up to ten events in one
night. He retained awareness throughout the events but was unable to speak. There
was no post-ictal confusion. The day after multiple seizures he is very tired. Interictal
EEG was unremarkable. Ictal video-EEG showed a run of rhythmic slow waves prior
to the event with muscle artefact obscuring the EEG during the events. He initially
responded to carbamazepine but suffered unacceptable side effects. Valproate was
ineffective but vigabatrin controlled the events. A trial ofwithdrawal of vigabatrin
produced recurrence of the nocturnal seizures. An MRI was reported as showing
scattered non-specific white matter changes.
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Case IV: 11
The younger brother of case IV: 10 presented with nocturnal seizures aged 9 years.
He would have a loud groan, brief tonic stiffening of his limbs followed by clonic
jerking of upper and lower limbs for 5-20 seconds. He often fell out of bed. He had
no recollection of the events. An interictal EEG showed occasional runs of slow
waves and low amplitude spikes at the surface. An ictal EEG was largely obscured
by muscle artefact but showed fast activity at the vertex during the event. An MRI is
normal. He has some specific learning difficulties with poor verbal and memory
skills. His seizures were controlled on a combination of lamotrigine and vigabatrin.
He has had one episode of clonic status epilepticus lasting 40 minutes.
8.3.2 Molecular Genetic and expression studies
8.3.2a Family D
DNA studies in case IV: 1 and IV:2 2 failed to show linkage to the chromosome 15
markers that had been reported in family D. Both boys were then tested for the two
known CHRNA4 mutations on chromosome 20. They both had a C to T transition in
amino acid position 248 leading to the replacement of serine by phenylalanine
(S248F) in the second transmembrane segment of the receptor channel. This
mutation had previously been reported in the first Australian family with ADNFLE.
The rest of family D were then tested for the same mutation. All affected members
and the one obligate carrier tested (11:6) were found to have the mutation except for
case IV:9. All unaffected cases (IV:6, IV:8,111:1) do not have the mutation.
Haplotype analysis shows that in family D the gene is embedded in the same three marker
haplotype as the Australian family, raising the possibility of a founder effect. Intragenic
CHRNA4 and KCNQ2 markers show an identical haplotype segregating with the
mutation in family D and the original Australian kindred . However, the table of allele
frequencies shows that the most common allele of each marker is the one present in the
haplotype. This data is compatible with either independent mutation or founder effect.
124
Functional studies on the S248F mutation were described by Daniel Bertrand and
colleagues following the identification of the same mutation in the Australian family
(Bertrand et al 2002). Initial studies on the S248F mutation produced conflicting
results however co-expression of normal and mutant receptors showed a gain in
acetylcholine sensitivity.
8.3.2b Family S
Sequencing of the second transmembrane domain (M2) ofCHRNB2 revealed a
G—>A transition . This cl025G—>A mutation replaces a highly conserved valine with
methionine at position 287 (V287M) (Figure 8.3). The CF1RNB2 M2 domain amino
acid sequence is fully conserved between different species (Figure 8.4). Expression
studies show that the mutant receptor demonstrates an increase in acetylcholine
sensitivity when compared to wild type. This is present in the homozygous state and
when expressed with wild type (32 and a4 subunits.
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Figure 8.3 Electropherogram showing DNA sequence and position of the





Figure 8.4 The M2 domain amino acid sequence of the (32 subunit of the
neuronal nicotinic acetylcholine receptor shows evolutionary conservation
M2 domain amino acid sequence
Mutated allele













The initial clinical and molecular study of family D demonstrates the importance of
detailed history taking and knowledge of all the paroxysmal disorders that can mimic
epilepsy. Case IV:9 was misdiagnosed as having frontal lobe epilepsy when he had
the much commoner disorder of non-REM partial arousals from sleep manifesting as
night terrors and sleep walking. This error in phenotyping was further compounded
by genetics colleagues in Australia as they chose to screen just one case, IV:9, for
the two known mutations in CHRNA4 on chromosome 20 and for novel mutations in
the gene. They did not screen the proband. Linkage studies showed that individual
IV:9 and the proband (IV:7) inherited different copies ofCHRNA4. This was felt to
give further evidence that this locus was not involved in the Scottish family. Studies
also appeared to show weak linkage to chromosome 15. This was an attractive
proposition as there is known to be a cluster of three nicotinic acetylcholine receptor
genes on this chromosome. Family D were therefore published in 1998 as not having
a CHRNA4 mutation (Phillips et al. 1998). This has been corrected with a letter to
the journal.
When case IV:2 was referred he too was suspected as having a parasomnia because
ofhis mother's history. The importance of video recording and particularly home
video recording was emphasised as it was the video of a nocturnal event taken by his
mother that helped make the diagnosis of frontal lobe epilepsy. Direct questioning
then revealed unreported events in his brother, case IV: 1 and further questioning
revealed a link to family D through the estranged father of the boys who was
clinically not affected by ADNFLE.
This link led to the correct genetic diagnosis in all affected members of family D.
The genetic study on family S was submitted for publication at the same time as a
study of an Italian family with ADNFLE who were found to have a CHRNB2
mutation (De Fusco et al 2000; Phillips et al 2001). These reports were the first to
report CHRNB2 as a new idiopathic epilepsy gene. The Italian family had a
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Val287Leu mutation at exactly the same position in the gene as the Scottish
Val287Met mutation. This suggests this is a functionally important part of the gene.
In Family S 10 (6F;4M) living affected individuals (aged 13 to 82 years) with the clinical
phenotype ofADNFLE were identified. Eight had the Val287Met mutation in CHRNB2
as does obligate carrier 111:4. In family D, 6 (3F:3M) family members aged between 16
and 50 years had ADNFLE. The median age of onset was 10 years in family S (range 6 -
18 years, mean 11.1 years) and 12.5 years in family D (range 6-15 years, mean 11.3
years). All affected individuals were normal intellectually. In both families there was a
delay (of up to 9 years) between onset of seizures and diagnosis of epilepsy and the
diagnosis ofADNFLE was only made after the presentation of a child with a severe
phenotype to a paediatric neurologist.
Psychological morbidity featured prominently in both families (McLellan et al, 2003).
Psychological complications had not been specifically mentioned in previous reports of
families with ADNFLE. Individuals from both families experienced psychological
problems including depression, low self-esteem, a hysterical gait disorder and school
refusal. Two children had been thought to have a psychiatric disorder prior to the
diagnosis of epilepsy being established. However, only a few families with ADNFLE
have been reported in detail to date and therefore it is not possible to know definitely
whether the psychological difficulties in these 2 families are a non-syndrome specific
consequence of the delayed diagnosis and impact of the epilepsy on the individual, are
unrelated to the epilepsy or indeed a behavioural phenotype influenced by the CHRN
mutations. Since then three further papers have reported memory deficits, psychotic
disorders, mood disorders and incapacitating apathy in families with ADNFLE
(Magnusson et al, 2003; Bertrand et al., 2005; Derry et al., 2008). It is therefore highly
likely that these symptoms are related to receptor function in the brain.
The natural history of the disorder in both families revealed remission in teenage years,
persisting after withdrawal ofAEDs, or improvement after puberty. However, an 81 year
old lady from family S recalls nocturnal seizures since teenage years. She had 2 seizures
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in her 7th decade and one in her 8th. Her cranial CT scan and EEG were normal at the age
of 77 years. The probands from both families had the most severe phenotype. The
proband from family S presented at the age of 11 years and had up to 50 seizures each
night which are now well controlled on clobazam and topiramate. The proband from
family D has up to 70 seizures at night and these persist at the age of 18 years, 12 years
after his initial presentation.
All reported and videotaped seizures except for one isolated occasion in case IV:8 of
family S, arose in sleep and typically occurred in clusters. In both families the seizures
were brief and of frontal lobe semiology. These were stereotyped in each individual at a
particular age but the seizure semiology was influenced by age. For example the proband
from family D presented aged 6 years with stereotyped seizures characterised by dystonic
posturing of the right upper limb followed by screaming and irregular thrashing
movements of all limbs. Aged 18 his seizures comprise of arousal with a partial motor
seizure affecting either side of the face and sometimes either upper limb. Video tape
recordings of the changing semiology over time are available in this individual.
Respiratory symptoms or signs comprising hyperventilation or a subjective sensation of
difficulty in breathing during the seizure was present in 5/10 of family S and 2/6 of family
D. In 3/10 in family S and 1/6 in family D there were seizures with reported secondary
generalisation. 5/10 members of family S had episodes of facial grimacing sometimes
associated with stereotyped vocalisation.
5/6 members of family D and 7/10 individuals from family S were treated with
antiepileptic drugs (AEDs). Carbamazepine was the most frequently used (4/7 in family S
and 4/5 in family D) and was the most effective AED. 3/7 members of family S and 1/5
from family D had been on three AEDs or more.
Neuroimaging was performed in 9/16 individuals and was normal except for non-specific,
probably unrelated white matter abnormalities in one case. Inter-ictal EEGs were
performed in 13 and was abnormal on one occasion (left fronto-temporal slow waves) in
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one individual (IV:8 family S). Ictal EEG was performed on 4 individuals revealed
muscle artefact only.
Comparison of the two families shows a very similar epilepsy phenotype, with mean age
of onset of 11.1 years in family S and 11.3 years in family D. This compares to 8.5 years
in the Australian family and 8.6 years in the Norwegian family (Scheffer et al. 1995;
Steinlein et al. 1997). In the Australian family the worst affected individuals had onset at
<1 year, however in family S and D the probands had onset at 11 and 6 years respectively.
Therefore onset in mid or late childhood does not necessarily imply a less severe epilepsy
phenotype. Although the disorder tends to remit or improve following puberty, one
member of family S continued having seizures into her 8th decade emphasising that
ADNFLE should be considered in the differential diagnosis of nocturnal events in adults
as well as children.
Initial in vitro studies of these mutations simulating the homozygous state, using oocyte
expression systems, led to some conflicting data (Bertrand et al 1998; Phillips et al. 2001).
However, co-expression of normal and mutant receptors, to simulate the heterozygous
state, showed increased acetylcholine sensitivity for both mutations (Ser248Phe of
CHRNA4 and Val287Met of the CHRNB2) (Bertrand et al 2002). This suggests that a
gain of receptor function is the basis for the epileptic seizures and their common clinical
phenotype.
A third nicotinic acetyl choline receptor subunit, the a2 subunit (CHRNA2), has been
reported in a Sardinian family who have ADNFLE characterised by nocturnal wandering
and epileptic fear (Aridon et al, 2006). Functional studies showed this mutation increased
sensitivity to acetylcholine.
A question often posed when considering ADNFLE is why should a genetic abnormality
produce a focal epilepsy? Two individuals from family D, cases IV: 1 and IV:2,
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participated in a study in Paris coordinated by Fabienne Picard using positron emission
tomography (PET) to look at nicotinic acetylcholine receptor (nAChR) density (Picard et
al 2006). 8 individuals with ADNFLE were compared to a group of controls. A significant
increase in nAChR density was found in the cerebellum and diencephalon ofADNFLE
cases. A decrease in receptor density was found in the right dorso pre-frontal cortex.
Fluorodeoxyglucose PET studies in the ADNFLE patients showed reduced glucose uptake
in the right orbitofrontal cortex. This in vivo study supports regional expression of the
receptors as one of the reasons for the focal semiology
This comparative study of two Scottish families with ADNFLE from similar ethnic and
geographical backgrounds shows that despite having mutations in genes coding for
different subunits of the neuronal nicotinic acetylcholine receptor, the phenotype is
largely identical in both families. This is likely to be due to the fact that the overall
consequence of each mutation on the function of the receptor is similar. This study adds
further evidence that the phenotype ofADNFLE is due to the functional consequences of
mutations on the nicotinic acetylcholine receptor.
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Chapter 9
Dravet Syndrome and other SCN1A
Related Epileptic Encephalopathies
9.1 Introduction
Dravet Syndrome, also known as severe myoclonic epilepsy in infancy (SMEI), is a
severe form of infantile onset epilepsy first described in 1978 by Charlotte Dravet, a
French paediatric neurologist working in Marseille (Dravet 1978). The Marseille
group and others went on to report further series of patients and it became clear that
this was an epilepsy syndrome seen by all child neurologists with a recognisable
pattern of seizure types, temporal evolution and EEG features (Dravet 1992). In 2001
Claes et al. were the first to show that the syndrome is associated with de novo
mutations in the gene encoding for the al subunit of the neuronal sodium channel
(SCN1A) (Claes et al, 2001).
Voltage gated sodium channels are essential for the initiation and propagation of
action potentials in the nervous system. They are made up ofmore than one subunit
type (heteromultimeric), consisting of a single large pore forming a subunit and one
or two small auxiliary P subunits. The a subunit alone may be sufficient for channel
function (George, 2005). The P subunits influence levels of cell surface expression,
voltage dependence and kinetics of the channel (Meisler & Kearney, 2005). The a
subunits are large transmembrane proteins consisting of approximately 2,000 amino
acids. They have 4 homologous domains which are highly conserved through
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evolution. Each domain contains 6 transmembrane segments (SI-6). The 4 domains
make up the channel through which sodium ions can pass down a concentration
gradient during the generation of the action potential. The S4 segment has a voltage
sensor role and the S5-6 loop region controls ion selectivity and permeation ( Figure
9.2).
Mutations in the SCN1A gene are associated with a variety of epilepsy phenotypes.
The familial syndrome of generalised epilepsy with febrile seizures plus (GEFS+)
was first described by Scheffer and Berkovic in 1997 (Scheffer & Berkovic, 1997).
The syndrome is now in the process of being renamed genetic epilepsy with febrile
seizures plus. The term describes a family and not an individual. The word "plus"
refers to the variety of other epilepsy phenotypes in a family where the predominant
seizure type is simple febrile seizures. These include febrile seizures beyond 6 years,
febrile and afebrile generalised tonic clonic seizures, febrile seizures plus absences,
focal epileptic seizures and myoclonic astatic epilepsy. The presence of focal and
generalised seizures and their sometimes artificial distinction in epileptology has led
to "genetic" being preferred to "generalised" in GEFS+ (Livingston et al 2009).
Figure 9.1 shows the pedigree of a Scottish family with GEFS+ that I studied and
wrote up in 1999 in an essay submitted for the ILAE Millenium Gowers Prize with
the title "Ion channels and epilepsy: an excitingfuture" but which has not been
published elsewhere. This illustrates the variety of phenotypes and bilineal
inheritance that frequently occurs in these families. This family does not have a
mutation in a gene known to be associated with the syndrome. GEFS+ was first
associated with a mutation in the pi subunit in a large Australian family (Wallace et
al 1998). However pi subunit mutations are uncommon causes ofGEFS+ as are
mutations in the a2 subunit (SCN2A) and the y2 subunit of the GABAa receptor
(GABRG2) (Wallace et al 2001, Baulac et al 2001). The vast majority are related to
mutations in SCN1A but even then mutations are only found in about 10% of large
families with GEFS+ (Escayg et al 2000). The variety of phenotypes in GEFS+ is
most likely related to other modifying genetic factors in each individual. The Scottish
family illustrated in figure 9.1 has one individual with severe myoclonic epilepsy in
infancy / Dravet Syndrome. The extension of the GEFS+ spectrum to Dravet
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Syndrome was first reported by Singh et al. and subsequently Claes and colleagues
went on to identity de novo SCN1A mutations in Dravet Syndrome (Singh et al.
2001, Claes et al 2001).
Identification of the genetic basis ofDravet Syndrome has allowed the study of the
phenotypic spectrum of epilepsies associated with mutations in SCN1A. In this
chapter I will summarise my contribution to this field, including work which I have
done in collaboration with clinical and molecular genetic colleagues in Australia
prior to being able to analyse the gene in Glasgow.
Dravet syndrome typically presents in the first year of life, usually in children with
no pre-existing developmental problems who develop prolonged febrile generalised
clonic or hemiclonic epileptic seizures. There is an evolution into other seizure types
including myoclonic, focal, atypical absence and atonic seizures between the ages of
1 and 4 (Dravet 1978). The epilepsy is usually not responsive to standard anti-
epileptic medication and the children develop an epileptic encephalopathy, which
means that the epileptic activity in the developing brain alters brain development and
leads to cognitive and behavioural impairment (Engel, International League Against
Epilepsy 2001). Carers see their child with normal development suffer uncontrollable
seizures, develop a significant learning disability and sometimes a motor impairment
with pyramidal signs and ataxia. Seizure types within Dravet Syndrome such as
status epilepticus may be life threatening and sudden unexpected death in epilepsy
can occur. Borderline or borderland subtypes ofDravet Syndrome have been
described by several authors and refer to children who lack some of the key features
ofDravet Syndrome / SMEI including myoclonic seizures, generalised spike wave
on EEG, have later onset and who may have a relatively good cognitive outcome
(Ohmori et al 2003; Fukuma et al 2004). These phenotypes have been given a variety
ofnames including SMEB and intractable childhood epilepsy with generalised tonic
clonic seizures (ICEGTC) (Fujiwara et al 2003).
In conversations with Professor Ingrid Scheffer from Melbourne relating to the
phenotypic spectrum of SCN1A mutations, I discussed the clinical observation of
134
my supervisor Professor John Stephenson that cases of so called "whooping cough
vaccine damage" or "vaccine encephalopathy were in fact Dravet Syndrome. I
suggested that with the recognition of a genetic basis for Dravet Syndrome this
observation could be tested. This discussion was one of the reasons that the
Australian group decided to re-open their study of SCN1A related epilepsies (Ingrid
Scheffer - personal communication).
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Figure 9.1
Pedigree of Scottish family with GEFS+ illustrating the variety of phenotypes
including SMEI / Dravet syndrome and bilineal inheritance.
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9.2.1 Phenotypic spectrum of SCN1A related disorders
Cases of infantile onset epileptic encephalopathy including cases with a clinical
diagnosis ofDravet Syndrome were identified from my own practice and that ofmy
colleagues Dr Mary O'Regan and Dr Robert McWilliam. All individuals were under
continuing follow up in the Fraser ofAllander Neurosciences Unit. The definition of
epileptic encephalopathies as "disorders in which there is a temporal relationship
between deterioration in cognitive, sensory andmotorfunction and epileptic activity
comprisingfrequent seizures and/or extremelyfrequent 'interictal paroxysmal
activity" was used to define cases. (Nabbout and Dulac, 2003). Case records
including neuroimaging, EEG studies and other investigations were reviewed.
Special attention was given to the onset of epileptic seizures, their semiology over
time including video recordings, and EEG features over time. Early developmental
history and trajectory were recorded with details of any regression in abilities and
nature of any learning disability. Cases were included if neuroimaging was normal
and there was no underlying diagnosis identified. Cases were classified as Dravet
Syndrome / SMEI, borderline Dravet Syndrome / SMEB or unclassified epileptic
encephalopathy. The classification ofDravet Syndrome was based on onset of
generalised or hemiclonic seizures in the first year of life in a developmentally
normal infant who went on to develop a variety of other seizure types including
myoclonus in association with an epileptic encephalopathy and generalised spike and
wave on EEG. SMEB was defined as the features ofDravet Syndrome without
certain features such as generalised spike and wave and myoclonus or onset in the
second year.
With informed consent DNA samples were collected and forwarded to Professor
John Mulley's molecular genetic laboratory in Adelaide. All 26 exons of SCN1A
were amplified by polymerase chain reaction (PCR) and analysed by denaturing high
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performance liquid chromatography (DHPLC). Regions in which abnormalities on
DHPLC were detected underwent bi-directional sequencing.
The clinical and molecular genetic data were included in a collaborative study with
other cases primarily from Australia, New Zealand and Canada. The evaluation of
the larger group was coordinated by Professor Ingrid Scheffer in Melbourne.
9.3 Results
15 cases with infantile onset epileptic encephalopathy were included in the study. 6
cases had a diagnosis ofDravet Syndrome, 1 with SMEB and there were 8 with
unclassified epileptic encephalopathies. The 7 cases with Dravet Syndrome and
SMEB had a range of age of onset from 3 months to 12 months. The group
comprised four females and one male. All had normal development before their first
seizure and none had a family history of epilepsy or febrile seizures.
6/7 had their first seizures in the context of a febrile illness. 2/7 cases had their first
seizure within 24h of a DPT immunisation. In one case this was the first set of triple
vaccine in the other the third set. 4/7 had febrile status epilepticus (30 minutes) as
their first seizure. Of these 2 were hemi-clonic status epilepticus. All 4 were admitted
to the intensive care unit. 2 cases had clusters of recurrent seizures on the first day of
seizures, one several brief 1-2 minute generalised convulsions and the other recurrent
myoclonic seizures causing limb jerks and head drops. All 6 Dravet Syndrome cases
had hemi-clonic epileptic seizures at some point in infancy. One case who presented
with a brief febrile seizure at 7 months began having episodes of status epilepticus at
1 year of age.
All 6 cases ofDravet Syndrome had different types of epileptic seizures with
myoclonic and focal epileptic seizures from the second year. Initial interictal EEG
studies were normal in 5 patients but all patients had abnormal EEGs with time with
generalised spike and wave in 5 cases. Focal spike and wave abnormalities were seen
in all cases.
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4/7 developed movement problems including the case with SMEB. This individual
had a mild degree of ataxia with an intermittent exercise induced movement disorder
characterised by brief limb dystonia. 4 cases developed upper motor neuron signs
with one having severe truncal hypotonia and three developing a diplegia with toe
walking.
All cases had refractory epilepsy with between 8 and 22 medications prescribed to
each child (mean 14). However all patients did show significant improvement with
certain medications. Three improved with triple bromide elixir (one stopped due to
side effects) and five have had significant improvement in seizure control with
stiripentol.
All cases had an epileptic encephalopathy with acquired learning disability. This
varied from mild to profound (see case summaries). One child had sudden
unexpected death in epilepsy.
6/7 cases had mutations in the SCNIA gene. Details of the mutations are listed in
table 9.1. One case ofDravet Syndrome did not have an SCNIA mutation.
9.3.1a Case Summaries
Case # Clinical Diagnosis mutation amino acid change
Case 1 Dravet Syndrome c.3714A>C p.Glu1238Asp
This 1 ly old female first presented aged 3 months on the day of her first DPT
immunisation. That day she fed poorly, became febrile at 40 degrees celcius and had
a prolonged generalised clonic seizure requiring intensive care unit admission,
intubation and ventilation. As an infant she had prolonged generalised clonic
seizures, clusters of brief generalised clonic seizures particularly with febrile
illnesses and myoclonic seizures particularly in the morning. In the 2nd year she had
prolonged hemi-clonic seizures. Development was normal in early infancy but by 18
months to 2 years developmental problems were evident.
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Initial EEG was normal. At 1 year, episodes of right sided spike and slow with photic
stimulation were present on EEG. Frequent generalised spike and slow wave bursts
occurred in later interictal recordings. Generalised spike wave bursts were associated
with myoclonic jerks. A focal epileptic seizure with secondary generalisation was
captured on video- EEG telelemetry with spike and slow wave commencing on the
right and spreading to all areas. Later in life there was no response to photic
stimulation. Age 3 years she saw Jean Aicardi who said "By certain aspects it looks
like severe myoclonic epilepsy but the onset was a bit early.'" She has had several
episodes of obtundation status lasting a few days characterised by markedly reduced
responsiveness, some peri-oral myoclonus and a diffusely slow background EEG
with very few associated sharp waves.
Multiple medications were tried - lamotrigine, topirimate, sodium valproate,
clonazepam, phenobarbitone, levetiracetam. She did respond to triple bromide but
this had to be stopped because of severe rash and irritability. Her seizures are now
much better controlled on a combination of stiripentol and clobazam. She may go
several weeks without a seizure. She has truncal ataxia and pyramidal tract signs
with a diplegia. She can walk independently for short distances. She has severe
global learning disability with no speech. She smiles responsively to her family
members and vocalises but has autistic features with active gaze avoidance of
strangers.
A novel missense mutation was detected in SCN1A causing a significant amino acid
change in the S1-S2 linker in domain three of the channel. Parents did not wish to be
tested.
Case 2 Dravet Syndrome c.3733C>T p.Arg1245X
This 10 year old female had her first seizures at age 7 months. She had five
generalised clonic seizures 1-2 minutes all in the context of a viral upper respiratory
tract infection. Early interictal EEG was normal. She continued to have clusters of
brief generalised seizures mostly with febrile illness every month or so. At 1 year she
began to have prolonged febrile convulsions with post ictal hemiparesis. At 22
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months she was noted to have normal development. Myoclonic seizures were present
by two years at which time interictal EEG showed generalised spike/polyspike and
wave as well as multifocal independent spike and wave complexes. Ictal EEG during
a bout ofbrief generalised clonic seizures showed right or left hemisphere spiking
which then generalised. MRI in 1998 was normal. She was unresponsive to sodium
valproate, pyridoxine, lamotrigine, clonazepam, carbamazepine and acetazolamide.
She has developed a motor disorder with toe walking and a diplegic gait.
She has had cognitive regression with a severe learning disability and an acquired
autistic phenotype. Last year she was commenced on stiripentol in combination with
clobazam. Her seizures for the first time since infancy are now controlled. She is
seizure free but her behaviour is now very difficult to manage. Her parents prefer her
to be seizure free and difficult to control. She is now on risperidone.
She has a truncating mutation in the S1 region of domain 4 of the SCN1A channel.
The mutation has been reported in two other cases ofDravet syndrome (Nabbout et
al 2003)
Case 3 Dravet Syndrome c.1687delC p.Lys563TyrfsX60
This 14 year old girl presented age 5 months with a 40 minute hemi-clonic epileptic
seizure during an upper respiratory tract infection with a fever of 38 degrees celcius.
Over the next 6 months she had about 2 hemi-clonic seizures per week affecting her
right or left side lasting about 20 mins. with post ictal weakness. Seizure types from
the second year have been complex partial, myoclonic, bouts of generalised clonic
seizures, generalised and hemi-clonic status epilepticus. Until recently she had
seizures on most days with the longest time being 12 days between seizures. The
initial EEG at 5 months was normal. By one year her EEG showed generalised
polyspike and wave bursts asociated with myoclonic jerks. Medications have
included vigabatrin, clonazepam, pyridoxine, carbamazepine, triple bromide,
clobazam, lamotrigine, acetazolamide, primidone, sodium valproate, ketogenic diet,
tiagabine, and topirimate. She has had a dramatic response to stiripentol. This was
initially commenced in combination with valproate and clobazam. Seizures reduced
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in frequency however she had significant side effects. I stopped the valproate and
was able to increase the stiripentol further with disappearance of the side effects. She
went 6 months without a seizure.
Now she has brief complex partial seizures once every two weeks or less.
She has moderate to severe global learning disability with an acquired autistic
phenotype. Since her epilepsy has been better controlled she is less passive, more
determined and her behaviour is more difficult to manage.
She has a novel de novo frameshift mutation in the SCN1A gene predicted to cause
truncation of the protein and sited in the domain I to domain II linker region.
Case 4 SMEB c.1876A>G p.Ser626Gly
This 11 year old boy had normal development prior to his first seizure aged 1 year.
Between 12 and 18 months he had 12 febrile seizures some ofwhich were prolonged
to 30 minutes. He then went on to have generalised seizures about every two weeks.
He began to have focal seizures at about 214 years. The longest he ever went between
seizures was about 2-3 weeks. At age 5 he had febrile seizures and development
was said to be normal. Between age 5 and 6 years he developed myoclonic seizures
and atypical absences. EEG initially was normal but at age 6 years showed high
voltage polyspike bursts with a generally slow background. EEG showed
photosensitivity age 10 years though this had not been present earlier. From the age
of 5 years he had cognitive decline and had mild to moderate learning disability. He
developed ataxia and a diplegic gait and an intermittent dystonic movement disorder
triggered by exercise. He has been treated with 11 medications with a partial but not
sustained response to bromide and stiripentol. The trials of both these medications
may not have been for sufficient time. This boy died with a diagnosis of sudden
unexpected death in epilepsy. He has a novel missense SCN1A mutation sited in the
domain I to domain II linker region.
Case 5 Dravet Syndrome c.3462delT p.Ser1155AlafsX9
This 14 year old male presented age 7 months with generalised clonic status (45 min)
associated with a febrile illness and upper respiratory tract symptoms. After
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discharge from the ICU he was noted to have myoclonic seizures. He had further
admissions with status epilepticus in first year some clearly hemi-clonic as well as
myoclonic, atonic and complex partial seizures. EEG at 7 months captured
myoclonic jerks associated with generalised polyspike bursts. He had a myoclonic
jerk during photic stimulation Interictal EEG has persistently shown generalised
polyspike bursts. Several seizures captured on EEG over the last ten years including
serial myoclonic evolving into generalised tonic and then clonic seizures (Figure
9.3a,b & Figure 9.4). He has had episodes of non-convulsive status. Medications
used included sodium valproate, vigabatrin, nitrazepam, carbamazepine, clonazepam,
ethosuximide, lamotrigine, phenobarbitone, acetazolamide, ketogenic diet and triple
bromide. His seizures improved with triple bromide to about one per week however
nocturnal seizures increased in frequency and he is now on stiripentol and clobazam
with a good response.
He has moderate global cognitive disability with an acquired autistic phenotype, poor
attention and concentration. Behavioural problems include aggressive outbursts. He
has a de novo, novel, frameshift mutation in the domain II to domain III linker region
predicted to cause truncation of the protein.
Case 6 Dravet Syndrome No mutation identified
This 15 year old male presented with a cluster ofmyoclonic seizures and generalised
clonic seizures on the day of his third DPT immunisation aged 11 months. He was
febrile (38.5 degrees celcius). Development was normal to this age. He was cruising
around furniture and knew 2 body parts. Video- EEG at presentation showed clusters
ofmyoclonic seizures associated with generalised spike and wave (Figure 9.5). Over
the next year he developed generalised tonic clonic, hemi-clonic seizures and
atypical absences. He had an epileptic encephalopathy with developmental
regression and loss of sitting ability. He was treated with 21 anti-epileptic
medications. Aged 15 he was having daily epileptic seizures with an EEG
characterised by polyspike and slow spike and wave. He had a trial of stiripentol
which reduced seizure frequency for several months however the effect was not
sustained. He has profound global neurodisability.
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Case 7 Dravet Syndrome c.596C>G p.Thr119Arg
This 13 year old girl presented age 7 months with a prolonged hemi-clonic epileptic
seizure, lasting 20-30 minutes, mainly affecting her right side and not associated with
fever. She was admitted to ICU. EEG in week after seizure was normal. She had
further hemi-clonic seizures lasting 10 to 40 minutes at about monthly intervals
thereafter with subsequent weakness of right or left side. She had myoclonic seizures
and brief partial seizures, 3-5 per week with secondary generalisation at times.
Interictal EEG at presentation was normal. Age 1 year runs post central theta with
unusual stereotyped complexes comprising low amplitude sharp, followed by high
amplitude slow wave (figure 9.6). Post ictal EEG has been slow however we have
never captured generalised polyspike and wave and there has been no abnormal
response to photic stimulation.
Medications have included rectal diazepam, paraldehyde, carbamazepine, sodium
valproate, phenytoin, pyridoxine, vigabatrin, phenobarbitone, lamotrigine and
clonazepam. Prolonged hemi-clonic seizures continued every few weeks to every
three months until she was started on triple bromide elixir aged 4 years. The
frequency decreased thereafter. In the last 4 years she has had only one seizure. She
has a general learning disability with full scale IQ in 1997 assessed at 48 using WISC
III. As her epilepsy became better controlled on bromide there was an identifiable
cognitive improvement with a full scale IQ of 59 and no major discrepancy between
verbal and performance tasks.
She has a novel, de novo, missense mutation in the N - terminal region of SCN1A.
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Figure 9.2
Cartoon of the a 1 subunit of the neuronal sodium channel with two auxiliary (3
subunits. There are four homologous domains with 6 transmembrane
segments (S1-6). The S4 regions are involved in the voltage sensor and the
S5-6 loop forms the ion selectivity pore.
• Positions ofmutations detected in Dravet syndrome cases 1,2,3,4,5, & 7.
Table 9.1 Mutations detected in the SCN1A gene
Case Mutation Domain Exon Mutation
1 c.3714A>C; p.Glu1238Asp DIIIS1-S2
linker
19 Missense
2 c.3733C>T; p.Arg1245X DIVS1 18 Frameshift/Nonsense
3 c.1687delC; p.Lys563TyrfsX60 DI-DII linker 11 Frameshift
4 c.1876A>G; p.Ser626Gly DI-DII linker 11 Missense
5 c.3462delT; p.Serl 155AlafsX9 DII-DIII linker 17 Frameshift
7 c.596C>G; p.Thr119Arg N-terminal 2 Missense
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Figures 9.3a & b. EEG of case 5. Focal epileptic seizure commencing with
right hemisphere sharp and slow evolving into generalised seizure with fast
spiking over all areas.
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Figure 9.4 Interictal sleep EEG of case 5 showing runs of focal spike and
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Figure 9.5 EEG in case 6 age 1 year. Generalised spike and wave in
association with a myoclonic seizure
v v y H/v v—^wv v
Figure 9.6. EEG in case 7 age 5 showing a diffuse poorly organised slow
background with focal spikes over the left hemisphere
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9.4 Discussion
The seven Glasgow patients discussed in detail here have been reported in a paper
describing the spectrum of SCN1A related infantile epileptic encephalopathies
(Harkin et al 2007). The two individuals with seizure onset within 24h ofDPT
immunisation have also been reported in another paper on SCN1A related
phenotypes (Berkovic et al 2006).
9.4.1 Molecular genetics
Dravet Syndrome has an estimated prevalence of 1 in 20,000 to 1 in 40,000 however
no large epidemiological studies have been performed and the identification of
increasing numbers of genetically proven cases suggests that these figures may be
underestimates (see Chapter 10 and Hurst 1990, Yakoub 1992, Lossin 2009). 5/6
(83%) of the classical Dravet syndrome cases in the Glasgow series had SCN1A
mutations and this reflects the 52/66 (79%) mutations detected in the larger study
group. Mutations were detected throughout the gene (Figure 9.1). In the 3.5 years
that we have been sequencing SCN1A in Glasgow we have detected a further 9
mutations in patients from the West of Scotland (Chapter 10). All the mutations in
the first report of SCN1A in association with Dravet Syndrome were truncating in
nature (7/7) and this was suggested as the reason why the phenotype was more
severe than missense mutations in GEFS+ (Claes et al 2001). However we detected
3/6 missense mutations and 3/6 truncating mutations. The figure of 50% missense
mutations in Dravet Syndrome is in accordance with other larger subsequent studies
including the infantile encephalopathy study where the figure was 20/52 (40%)
(Harkin et al 2007). 5/6 (83%) of the mutations in the Glasgow series were novel
with 80% being novel in the wider study.
Nonsense, frameshift, splice site mutations and gross rearrangements such as
deletions or duplications would be expected to cause truncation of the protein and
haplo-insufficiency. The case for a missense mutation being pathogenic is based on
several pieces of evidence. A de novo mutation in a de novo disease is more likely to
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be significant. If the mutation affects a residue that is conserved within different
sodium channel subtypes and between different species (evolutionary conservation)
then it is likely to be significant. If the mutation causes a significant amino acid
change in a functionally important part of the gene it is more likely to be significant.
Functional studies are the gold standard for showing that a mutation is pathogenic
but they are not practical at present outside the research environment and studies in
different models can produce differing results. Work on different mutations in
SCN1A originally has produced conflicting results with some showing gain of
function and others showing loss of function (Spampanato et al 2003; Mantegazza et
al 2005). More recent work, particularly on mouse models, has suggested that the
epileptic phenotype is caused because the sodium channel has a critical role in the
function of inhibitory GABA interneurons (Yu et al 2006; Ragsdale 2008). This
model suggests that mutations cause reduced excitability ofGABAergic neurons and
widespread loss of brain inhibition. The extensive distribution of these GABAergic
interneurons, including in the cerebellum, might explain some of the motor
manifestations seen in SCN1A related encephalopathies. There are likely to be more
than one mechanism through which mutations cause epilepsy and a great deal of
translational research work is ongoing. In an individual the rest of the genetic
background is likely to influence the clinical expression of the gene mutation.
9.4.2 Clinical features
One of the Glasgow cases (case 4) was classified as SMEB because he had onset of
seizures outside of the first year of life. His phenotype in infancy and early childhood
was of febrile seizures, short and prolonged and generalised tonic clonic seizures.
His cognitive abilities were reported as normal until age 5 when his seizures became
more difficult to control. He didn't have myoclonic seizures until 5 years. Despite
what may be regarded as a milder phenotype he died at the age of 13 with sudden
unexpected death in epilepsy (SUDEP).
There is a significant mortality associated with Dravet Syndrome and its subtypes.
Some authors have suggested that it may be as high as 10-20% in childhood due a
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variety of causes including status epilepticus, sudden unexpected death and
accidental drowning (Dravet 1992, Dravet 2002). The incidence of SUDEP in adults
is unknown.
We recently reported a family with GEFS+ and a novel missense mutation in
SCN1A in which two individuals died of SUDEP (Hindocha et al 2008). SCN1A is
expressed in cardiac muscle and the sino-atrial node but it has as yet not been shown
to be implicated in cardiac arrhythmias. This family suggest their may be shared
mechanisms for the epilepsy and sudden death. The prevention of SUDEP is of
course a major clinical and research goal therefore any clues to molecular
mechanisms are important.
The presentation of 6/7 of our cases in a febrile illness is typical ofDravet syndrome,
with large series suggesting presentation with febrile seizures in 60-70% or by
elevated temperature such as immersion in a hot bath, as is often the case in Japan
(Ohki 1997). The presentation with febrile status epilepticus and ICU admission is
also typical. Recurrent hemi-clonic status in infancy is strongly suggestive ofDravet
Syndrome.
4/7 of our cases developed a progressive movement disorder in addition to the
epileptic encephalopathy. All had a degree of ataxia. This is a common finding in
Dravet Syndrome and may be difficult in early infancy to distinguish from side
effects of medication. Case 6 who did not have an identifiable mutation had the most
profound neurological decline both cognitive and motor. He was completely
dependant as a teenager, gastrostomy fed, with no sitting balance, central hypotonia
and pyramidal signs in his limbs. The 3 cases who developed a diplegia with
pyramidal signs all had epilepsies which followed different courses and had variable
cognitive outcomes. Refractory epilepsies of any aetiology may be associated with
movement problems most likely due to the involvement of cortical - basal ganglia
and cortical-cerebellar neuronal networks in the abnormal electrical activity.
However movement disorders and pyramidal signs are frequently reported in Dravet
syndrome and the features in our three patients suggest that regional expression of
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the mutated channel, much as in episodic ataxias and epilepsy, may play a role in
some individuals that is independent of the severity of the epilepsy. Paroxysmal
dystonia was recognised in case 4, a feature that was reported in a series of 3
Japanese patients (Ohtsuka et al 2003). These authors noted that the movement
disorders were worse when their patients were treated with the sodium channel
blocker phenytoin but that it was still present even off this medication.
9.4.3 Medication response
All our patients had highly refractory epilepsies, with the use ofmultiple
medications, however all showed improvement with specific medications. In some
cases this was quite dramatic. The most effective medication in the group was
stiripentol. This was used in combination with clobazam with or without sodium
valproate. In one child who had seizures every day of her life since infancy,
introduction of this drug as a teenager stopped all seizures for 6 months. Stiripentol
appears to have two potential mechanisms of action. It is a cytochrome P450 inhibitor
therefore it can raise levels of other AEDs such as clobazam (Perez et al 1999). It
also has direct effects enhancing central GABA transmission and this, given the
concept ofDravet Syndrome as a GABA interneuronopathy, may be why it appears
to be specifically helpful in this syndrome when the vast majority of medications fail
(Quilichini et al 2006). There have been two randomised controlled trials showing
the effectiveness of stiripentol in Dravet syndrome however both had a short duration
of follow up of only 2 months (Chiron et al 2000; Kassai' et al 2008). My own
clinical experience and that of colleagues is that stiripentol is helpful in the long term
however well designed studies have not been performed. As stiripentol is a potent
cytochrome P450 inhibitor it needs to be commenced with caution. Concomitant
medications may need to be reduced significantly and the children should be
monitored closely with regular adjustments to doses as demonstrated in case 3. My
clinical experience of the use of stiripentol in several Dravet syndrome patients has
been of a significant decrease, sometimes cessation, in seizures for several months
followed by a return of occasional seizures but never as frequent as prior to the
introduction of the medication.
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Bromides were the first antiepileptic medication available from the 19th century
however they were no longer used in most centres because of the high rate of side
effects. There have been case series reporting efficacy of bromides in Dravet
Syndrome. Bromides have been the treatment of choice in Japan with one study
showing moderate to excellent improvement in convulsive seizure frequency in 70%
of patients (Oguni et al, 1994). 3 of the Glasgow cases using bromides showed
reduction in seizure frequency with case 7 seizure free. Bromide levels need to be
monitored closely to reduce the risk of side effects.
Topirimate has been shown to be effective in reducing seizure frequency in several
open label or retrospective studies (Nieto-Barrera et al, 2000a; Kroll-Seger et al,
2006). Certain medications notably Lamotrigine and carbamazepine can increase
seizure frequency, particularly myoclonic and generalised clonic seizures (Guerrini
et al, 1998).
Better control of epileptic seizures should reduce the impact of the epileptic
encephalopathy and improve long term cognitive and behavioural outcomes however
this has not been demonstrated as yet. In the cases described one had an
improvement in IQ demonstrated as the seizures improved and several were said by
parents to be more alert, more confident and more focused in their actions. This
resulted in challenging behaviour in some children but this was far preferable to
families than their children having frequent seizures. The cognitive outcome in
Dravet syndrome has been regarded as universally extremely poor however the
potential to treat the epileptic encephalopathy effectively gives the hope that the
cognitive outcomes may improve. At the American Epilepsy Society Meeting in
2008 Chipaux et al reported cognitive and behavioural outcome in 64 patients. This
work is as yet unpublished but they reported that 42/57 cognitive evaluations in
children over 4 showed mild or moderate delay with only 7 showing severe delay.
They concluded that their study showed better cognitive and behavioural outcome
than previously reported and that this may be because of changing patterns of
treatment of the syndrome (Chipaux et al 2008).
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The most important factor in the therapy ofDravet syndrome will be early treatment
before the epileptic encephalopathy is established and cognitive decline occurs. This
will necessitate diagnosis as early as possible in the first or second year of life before
cognitive decline begins. Even three to four months of seizure freedom at this critical
developmental age, when infants are beginning to develop speech, use imagination
and develop their own independent personalities may have a major positive impact
on development. The role of molecular genetics in aiding early diagnosis is discussed
in chapter 9.
9.4.4 "Vaccine encephalopathy" and SCN1A mutations
Case 1 and case 6 had their first epileptic seizures within 24h of a DPT
immunisation. The family of case 6 had received "vaccine damage" compensation
and the family of case 1 were undertaking legal proceedings for "vaccine damage"
compensation. My supervisor Professor John Stephenson had taught me that in his
view children with so called "vaccine encephalopathy or "whooping cough vaccine
damage" in fact had Dravet syndrome. The genetic characterisation ofDravet
syndrome allowed this hypothesis to be tested.
Professor Stephenson had been involved in the at times heated debate relating to
"vaccine encephalopathy" in the 1970s and had been an expert witness in court. As
this issue was of such importance to public health policy, wider society, and the
politics of the day, much of this debate was carried out in the national press rather
than in the scientific literature. Figures 9.2a and b are cuttings from the Sunday
Times letters pages in May of 1977. In his letter John Stephenson makes the point
that it is the seizures that are damaging rather than the vaccine, and that it is also
possible that congenital abnormalities that produce epilepsy may present for the first
time at around the time of immunisation. He suggested that a long convulsion
brought on by the fever produced by the immunisation was important rather than
anything specific about the vaccination. This was a year before Charlotte Dravet's
first description of the syndrome.
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Figure 9.7a
John Stephenson's Sunday Times Opinion piece dated 22/05/1977




THE continuing campaign for
compensation to " whooping
cough vaccine-damaged" chil-
• clrcn seems to me to be com¬
pletely misguided. In the first
place we do not have any sound
evidence that the whooping
cough vaccine is ever a direct
cause of brain damage.
This is quite unlike the situa¬
tion with certain other vaccines
fsuch as that against smallpox)
where rarely an allergic inflam¬
mation of the nervous system
may result in permanent injury.
What is known is that very occa¬
sionally alter whooping cough
vaccine (as after any other
cause of fever) a child may take
a convulsive seizure with fever,
a febrile convulsion, which does
not stop quickly like most febrile
convulsions but continues for
more than half an hour.
We- call this medical emer-
Igency "febrile status epilep-
i licus," and its danger is that
it may result in a brain-scar
| from which epilepsy, can 3rise in
later life.--or .induce permanent
weakness of one side of the
body, so-called hemiplegia. The
mure widespread such, brain
damage, the more likely if there
| to be mental handicap in
i addition.
The important point is that
although this long convulsion
may-have been sparked..off by
■ the whooping cough vaccine, it
is the convulsion itself and not
the vaccine which is damaging.
This is vital, because we now
know how to prevent damage
from these febrile convulsions,
using injections which stop them
early and glucose infusions in
hospital which allow brain
function to repair. Except by
this indirect mechanism of
febrile status epilepticus. which
is preventable without altering
vaccination policy, we know »f
no means whereby whooping
cough immunisation leads lb
actual physical brain damage.
What then about the allega¬
tions that severe mental handi¬
cap can be induced by the vac¬
cination. without severe convul¬
sions having taken place'.' Can
Dr.J STEPHENSON
. Child's brain specialist
the function of the brain be
seriously impaired, without there
being any structural damage?
For' several years there has
been concern about this ques¬
tion. chiefly in relation to so-
called " infantile spasms," other¬
wise known as the West
syndrome because a Dr West
first observed and described the
condition in his own son (long
before the whooping cough
vaccination).
Infants with Wesi syndrome
lose interest and regress in
development at about the age
of six months; shortly after¬
wards they begin to have fre¬
quent brief forward-bending
spasms, easily confused with
simple colic. The brain waves
in a child with West syndrome
are totally disorganised (*" hyp-
sarrhythmia ") and it seems to
be this disorganisation of the
electrical activity of the brain,
rather than a physical damage,
which underlies the mental
handicap that usually follows.
For a long time it was uncer¬
tain whether whooping cough
vaccination could lead to West
syndrome in infants without any
other identifiable cause, but at
last there is excellent evidence
from Denmark that it does not.
The Danes altered the timing of
injections in their immunisation
programme five' years ago. and
no change in the age of appear¬
ance of West syndrome has
resulted.
A final question relates to
infants who already have eon-
genitally abnormal- brains. Such
babies may appear very " good."
placid and undemanding in the
first six months of life. Only
after this time, when the vac¬
cine is usually given, do peculi¬
arities of behaviour tend to show
themselves. Thus it is easy
to ascribe a cause to what ts
only a coincidence.
rt may be that sometimes the
misery attending immunisation
makes such an infant withdraw
and become isolated and out
of contact, because babies with
abnormal brains can be more
sensitive and vulnerable to dis¬
turbances of this kind. This
" isolation is readily confused
with actual vaccine damage, but
is amenable to treatment by
psychological methods.
It seems to me that all handi¬
capped children require "com¬
pensation " in the sense of
guidance and help towards inde¬
pendence. without any attach¬
ment of blame. Resources must
also be better directed towards
research into the prevention of
the real and not imaginan-
causes of brain damage a-
rnental handicap in children
Figure 9.7b Letters to the Sunday Times 29/05/77 in response to John
Stephenson's Opinion piece.
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Prior to routine childhood immunisation pertussis (whooping cough) was a major
cause ofmortality and morbidity. Between 1922 and 1932 there were about 73,000
deaths from about 17 million cases ofwhooping cough (Shorvon & Berg 2008).
Whooping cough itself is known to be associated with an encephalopathy in between
1 in 1,200-12,000 infections. The DPT vaccine was very effective but frequently
caused a brief febrile reaction and in some cases a febrile seizure. This febrile
reaction is thought to be largely related to the endotoxin of the whole cell vaccine.
Acellular vaccines are not as effective but have largely replaced the whole cell
vaccine as there are fewer adverse reactions. A small number of children after an
initial febrile seizure subsequently went on to develop a severe encephalopathy
associated with frequent epileptic seizures and cognitive regression. These children
were left with severe global neurodisability and total dependence on their carers. The
reports of "vaccine encephalopathy" provoked a great deal of public concern in the
United Kingdom and uptake of vaccination declined to 30% in the late 1970s
leading to an increase in cases ofwhooping cough and deaths related to the infection
in the early 1980s (Figure 9.3). Sweden and Germany stopped their vaccination
programmes for a period (Shorvon & Berg 2008).
Several epidemiological studies in the United Kingdom and several other countries
have failed to demonstrate evidence of a causal relationship between pertussis
immunisation and a severe encephalopathy. Despite this their remains a strong belief
of a causal relationship for many parents, lobby organisations and some physicians.
Nieto-Barrera et al in the Spanish literature had recognised the coincidence of the
first seizures in Dravet syndrome with the DTP immunisation (Nieto-Barrera et al
2000).
As well as the two Glasgow cases a further 12 cases who had an infantile onset
encephalopathy who had suspected "vaccine encephalopathy" were identified from
Australia, Canada and New Zealand. 8 had SMEI, 4 had SMEB and 2 had Lennox-
Gastaut Syndrome. 11 out of 14 of these cases had SCN1A mutations. There were 6
missense, 3 ffameshift and 2 nonsense mutations (Berkovic et al 2006). All the
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mutations were found in the SMEI or SMEB cases (Dravet Syndrome). Two
mutations had been previously reported in association with SMEI and the other
missense mutations affected highly conserved amino acids in areas where SMEI
mutations had been previously reported. Case 1 from Glasgow had a mutation. Case
6 did not have a mutation. He has been tested by MLPA and doesn't have a gross
rearrangement. We have not looked at GABRG2 or SCN2A as yet.
These findings are important in that they provide genetic confirmation for the
original hypothesis that "vaccine encephalopathy" is truly Dravet Syndrome in a
large proportion of cases. This has public health implications and medico-legal
implications for families wishing to seek vaccine damage compensation including
the family of case 1. In a further study, presented at the American Epilepsy Society
Meeting in 2008, the phenotypes ofDravet syndrome cases who presented with their
first seizure within 48h were compared to the phenotypes ofDravet Syndrome cases
that presented more than 4 days from an immunisation (Berkovic et al 2008). The
phenotypes were not significantly different. This suggests that the vaccination may
trigger the fever related to the first seizure but that this genetically determined
epilepsy would have presented even without the immunisation in the next febrile
illness. There was no difference in cognitive outcome between the vaccine proximate
and vaccine distant group.
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Figure 9.8
Confirmed pertussis infections and deaths compared with vaccine uptake
1980 to 1999. Department of Health, Health Protection Agency Website.













9.4.5 Phenotypes associated with Dravet Syndrome
The larger encephalopathy study in which the Glasgow patients featured described
other novel phenotypes associated with SCN1A mutations (Harkin et al 2007). A
phenotype called severe infantile multifocal epilepsy (SIMFE) was described in 5
patients, 3 ofwhom had SCN1A mutations. I have not seen a case of this disorder.
Ingrid Scheffer feels it can be distinguished from Dravet Syndrome and SMEB due
to the lack of generalised spike and wave on EEG, lack ofmyoclonic seizures, and
normal development with later cognitive decline than in Dravet Syndrome. Infants
have focal epileptic seizures including focal myoclonus as well as prominent
multifocal epileptiform discharges. Whether this is on the Dravet Syndrome / SMEB
spectrum or a clearly defined phenotype is uncertain until more cases are reported.
The complex genotype phenotype relationships in SCN1A related epilepsies makes
their classification difficult and a variety of names have emerged which sometimes
cause more confusion than illumination.
These include:
Dravet syndrome
Severe myoclonic epilepsy in infancy (SMEI)
Borderland (borderline) severe myoclonic epilepsy in infancy (SMEB)
SMEB - SW SMEI without spike wave
SMEB - M SMEI without myoclonus
SMEB-O SMEI with >1 feature not in keeping with SMEI
ICEGTC Intractable childhood epilepsy with generalised tonic clonic
seizures
I believe that all the phenotypes described above should be regarded as
forms ofDravet syndrome and should be described as such. Classical Dravet
syndrome has an onset at less than 12 months and is associated with prolonged
febrile generalised and hemiclonic seizures. In the second and third years other
seizure types emerge including myoclonus, atypical absences and focal seizures.
Cognitive decline is noted in the second year in association with an epileptic
160
encephalopathy. EEG may be normal initially but with time shows generalised spike
and wave. I think that classical Dravet syndrome need not feature prominent
myoclonus. This seizure type may take years to emerge. Borderland types ofDravet
Syndrome include those listed above but principally where the onset is after one
year, there is little or no cognitive decline and only refractory generalised seizures.
For classification and research purposes our group is going to suggest a simplified
classification for SCN1A related infantile epileptic encephalopathies. They should be
all termed Dravet syndrome unless they have a clearly distinct phenotype such as
SIMFE or rare cases of infantile spasms or Lennox -Gastaut. For research purposes
the division into classical and borderland forms is helpful to a degree as it
acknowledges that the edge of any syndromic classification is blurred and that within
this group there may be other genetic aetiologies. I suggest calling these groups







In chapter 9 I discussed the emergence of SCN1A as the most clinically relevant
epilepsy gene and the spectrum of infantile encephalopathies associated with the
gene. There is increasing evidence supporting specific treatment regimes for the
epileptic encephalopathy associated with Dravet Syndrome (Oguni et al 1994;
Chiron et al 2000; Nieto-Barrera et al 2000; Kassai et al 2008). As the
encephalopathy is associated with cognitive decline and permanent neurological
impairment aggressive focused therapy should be commenced as soon as possible
(Mullen & Scheffer 2009). However the clinical diagnosis ofDravet Syndrome is
based on recognition of seizure types, clinical course and EEG features and is often
not made until 2-4 years of age, even by experienced clinicians (Hattori et al 2008).
Most children with Dravet Syndrome will present to general paediatricians and
distinction between the first seizures in Dravet syndrome and common febrile
seizures is not easy to make. The gradual clinical evolution of the syndrome also
makes early diagnosis difficult. For these reasons and with the possibility of a
treatable epileptic encephalopathy there is likely to be an important role for a
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molecular genetic diagnostic service that can aid clinicians in making an earlier
diagnosis of SCN1A associated encephalopathies.
In late 2005 I established a joint clinical and molecular genetic SCN1A diagnostic
service in Glasgow. In this chapter I will detail how this clinical diagnostic service
was developed, report the nature of the mutations we have identified and the
emerging evidence that SCN1A genetic diagnosis can influence patient management.
I was successful in obtaining a grant from the Muir Maxwell Trust to purchase a
genetic sequencer based at the Duncan Guthrie Institute ofMedical Genetics, RHSC,
Glasgow dedicated to analysis of the SCN1A gene. The proposal was supported by
all the paediatric neurologists in Scotland and Su Stenhouse, head ofmolecular
genetics in Glasgow. The aim was to develop a joint clinical and molecular service. I
review all the clinical referral forms to the service, prioritise cases for testing and
discuss results on at least a weekly basis with Rachael Birch the clinical molecular
geneticist who does most of laboratory work. We then issue a joint clinical and
molecular genetic report. The service was originally established with charitable
funds, it then received National Services Division support in Scotland and the test
now has UK Genetic Testing Network approval. This is the only diagnostic service
for SCN1A in the United Kingdom and one of the few worldwide. As well as taking
referrals from the UK we now do clinical testing for several countries including
Australia and Ireland.
The principal focus of this study was to describe the nature of the mutations detected
in individuals with Dravet Syndrome (classical and borderline) related infantile
epileptic encephalopathy, to describe the age at onset of the first epileptic / febrile
seizure in this group and to audit the age of genetic diagnosis. We hypothesised that
genetic diagnosis would allow early diagnosis of SCN1A related epileptic
encephalopathies. This study was done on samples analysed within a clinical service
in a Clinical Pathology Accredited (CPA) laboratory therefore it reflects clinical
diagnostic standards rather than research standards.
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10.2 Methods
From early 2006 The Glasgow SCN1A service began to accept DNA samples. All
referrals are accompanied by a clinical form which I developed with external review
by Professor Ingrid Scheffer (Appendix 1). I review all referral forms and assign
each case a priority score (1 -5) and clinical diagnosis if possible. The score is based
on the diagnosis and the age of the child at time of referral. Scores 4 & 5 are given
for high degrees of clinical confidence that the child has either classical Dravet
Syndrome or Borderline Dravet Syndrome. Classical Dravet Syndrome (Dravet-C) is
defined as in chapter 9. Borderline Dravet Syndrome (Dravet-B) includes all classes
of SMEB as detailed in chapter 9 including intractable childhood epilepsy with
generalised tonic clonic seizures. Less severe phenotypes associated with GEFS+,
and in the context of a family history, are assigned a 3/5 priority score. Scores of
less than three were given when there was little evidence from the referral form that
the case had an epilepsy known to be associated with SCN1A gene mutations. If
cases were less than 2 years old and could have evolving Dravet Syndrome
phenotypes they were scored as 4 or 5. The scoring system was not used to reject
samples for testing but to prioritise testing particularly for young infants. Cases with
scores of 3 or greater automatically went on to MLPA analysis if sequencing studies
were negative.
SCN1A genetic sequencing and MLPA studies were performed by Rachael Birch
and colleagues. Molecular analysis was performed on genomic DNA extracted from
patients' venous blood. All 26 exons of the SCN1A gene were PCR amplified with
28 specific primer pairs and standard PCR conditions. Sequence products were run
on an ABI 3130 automated sequencer (Applied Biosystems) and data were analysed
using mutation surveyor software package (SoftGenetics V3.24). In cases where an
SCN1A mutation was found, available parental DNA was analysed by DNA
sequencing to determine whether a mutation occurred de novo or was inherited.
Sequence changes were distinguished from coding single nucleotide polymorphisms
and specific missense mutations were further validated by comparing them to a panel
of anonymous blood donors as a control population.
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In point mutation negative cases, when the phenotype suggested an SCN1A related
epilepsy, multiplex ligation-dependent probe amplification (MLPA) was performed
to detect large scale rearrangements in the gene. We used the commercially available
MLPA kit from MRC-Holland (PI37) and tests were conducted according to the
manufacturer's instructions. Electrophoresis of PCR products was performed using
an ABI 3130 sequencer and MLPA data were analysed using the GeneMarker
software SoftGenetics V1.8). The relative peak height of each exon was first
normalised by dividing the average relative peak heights of the internal control
probes. The normalised data for each peak was then quantified by dividing by the
average relative peak height of the corresponding exons of the control samples.
We analysed the clinical and molecular genetic data for those children with an
infantile onset epileptic encephalopathy, Dravet-C or Dravet-B, with particular
reference to nature ofmutation, age at first epileptic or febrile seizure and age at
genetic diagnosis. The date of final reporting of the mutation was used as the age of
genetic diagnosis. Statistical analysis was performed using SPSS version 15.0 (SPSS
Chicago).The study has been approved by the NRES UK.
10.3 Results
A total of 800 patients underwent SCN1A mutation screening from early 2006 to mid
2009. 280 fulfilled the diagnostic criteria for Dravet Syndrome with 200 classed as
Dravet-C and 80 as Dravet-B. We identified a total of 202 patients with SCN1A
mutations or deletions from these two groups. (Appendix). 191 mutations were
detected on sequencing and a further 11 had gross rearrangements of the gene
detected on MLPA. Mutations were detected throughout the gene (Figure 10.1).
Figure 10.2a shows the nature of the mutations in the whole group.
171/ 200 Dravet-C patients had a SCN1A mutation (85%). 77 (45%) were non-
truncating missense mutations, 4 (2%) were inframe insertions or deletions, 18 (11%)
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were splice site mutations, 29 (17%) were nonsense mutations, 32 (18.7%) were
frameshift mutations and there were 11 (6.4%) gross rearrangements (Figure 10.2b).
31/ 80 (39%) of the Dravet-B patients had a SCN1A mutation. 17 (55%) were non-
truncating missense mutations, 1 (3%) was an inffame insertions or deletions, 2 (6%)
were splice site mutations, 8 (26%) were nonsense mutations and 3 (9%) were
frameshift mutations (Figure 10.2c).
There was no significant difference in the frequency of truncating mutations (all
types apart from missense) between the Dravet-C and Dravet-B groups although all
the gross rearrangements detected by MLPA were all found in the Dravet-C group.
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The age of the first epileptic seizure was available for 194 / 202 mutation positive
cases (Figure 10.3). The age of first seizure ranged from 2 months to 26 months with
the mean at 6.2 months and median at 6 months with a standard deviation of 3.2.
94% of cases had seizure onset before their first birthday.
The median age at genetic diagnosis among all mutation positive patients was 4.5
years (Figure 10.4). The range was 7 months to 42 years. 13/202 patients were over
16 years of age at time of genetic diagnosis. 10 (5%) genetic diagnoses were made at
under the age of 1 year and 20% of genetic diagnoses were made under the age of 2
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Figure 10.4
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10.4 Discussion
We have identified a wide spectrum of mutation types in the SCN1A gene associated
with Dravet Syndrome in the 3'A years that our service has been functioning. This is
one of the largest series of SCN1A mutations reported. Only a French group with
243 mutation positive Dravet Syndrome cases collected over 5 years have reported
more cases (Depienne et al 2008).
The proportion ofpositive mutations in the whole Dravet Syndrome group was
202/280 (72%). This is similar to the report from France where the figure was
242/333 (73%). This figure has varied from 30-100% in the literature. The figure of
100% relates to the original important but small study of 7 patients with Dravet
syndrome / SMEI in which all the cases had truncating mutations (Claes et al 2001).
The figure of 33% was from a study of 24 patients classified as Dravet Syndrome /
SMEI from several centres where 8 mutations were detected (Wallace et al. 2003).
The percentage ofmutation positives will be related to the degree of phenotypic
detail available to classify the cases, the criteria used for classification and the
consistency of classification. Our referral form appears to be able to allow us to
classify patients appropriately and consistently. It is possible that classification by a
single clinician further promotes consistency. We identified mutations in 85% of
Dravet-C cases. Depienne et al. reported mutations in 78% of cases they termed
Dravet Syndrome. 2 clinicians classified all cases in Depienne et al. The lower
proportion of positive results in the Dravet-B group in our series is not surprising as
this is a more clinically heterogenous group.
46% of our cases had missense mutations which is very similar to the 42% described
by Depienne et al. The remainder detected on sequencing had nonsense, frameshift,
splice site and small deletions and insertions all predicted to cause premature stop
codons and truncation of the protein. We detected missense mutations throughout the
gene with no major "hot spots". The mutations are listed by exon in Table 10.1. The
missense mutations we identified in SCN1A tend to cause significant amino acid
changes in functionally important parts of the gene. We are currently analysing the
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Grantham score, a measure of the significance of the amino acid change, in all our
cases. The Grantham score is determined by composition, polarity and molecular
volume (Grantham R 1974). It is possible that the degree of change and the site of
change are major determinants of the pathogenicity of a specific mutation. Rarely a
missense mutation is associated with Dravet Syndrome in one individual and a
benign epilepsy syndrome in another within a GEFS+ family. In this situation other
modifying genetic factors are likely to be important.
We identified a further 11 cases with gross rearrangements of the gene detected by
MLPA (Figure 10.5; Table 10.1). All these cases had Dravet-C and represented 5.5%
of the total positive cases and a positive yield in 11/91 (12%) ofDravet Syndrome
patients who were negative on sequencing. 7 had whole gene deletions with 4 partial
gene deletions. We have not identified any exon duplications to date. The 3 partial
exon deletions in which parental samples were available were de novo. Depienne et
al (2008) reported that 14/234 (6%) of their 234 mutation positive cases had gross
rearrangements in the gene detected by MLPA. This represents 13% of their
sequencing negative Dravet Syndrome cohort. These figures are remarkably
consistent with our own and those ofMarini et al (Marini et al 2009). This group
found a frequency of 12.5% MLPA detected gross rearrangements in Dravet
syndrome patients negative on sequencing.
Sequencing of the SCN1A gene was able to detect mutations in 68% of our Dravet
Syndrome referrals. MLPA will detect a further 5% therefore our results support
utilising MLPA as a second tier test in a clinical service. The finding that all cases
with gross rearrangements in SCN1A had Dravet-C, supports offering MLPA to
cases with a phenotype consistent with Dravet Syndrome.
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Figure 10.5
Multiplex ligation probe amplification of the SCN1A gene. The upper panel
shows reduced peak sizes in a patient with a deletion including exon 2, exon
11 and exon 20. The lower panel is from a control panel showing normal
peak sizes as two copies of each exon are present.
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The age of first epileptic or febrile seizure was under one year in 94% of cases
emphasising that onset in the first year is a strong diagnostic indicator for Dravet
Syndrome. It also emphasises the developmental expression of the gene lesion in
early infancy. The median and mean age of onset are both around 6 months. 29% of
cases had onset at 2, 3 and 4 months which is exactly the time that children in the
United Kingdom have their first three sets of routine immunisations. This is typically
a period of parental concern and anxiety so it is therefore little surprise that parents
frequently link the onset of their child's problems with their immunisations. In the
1970s the first three immunisations were frequently spread out over a longer period
in infancy (2, 4 and 6 months) therefore encompassing the same period as 65% of
first seizures in Dravet Syndrome.
Dravet-C by definition has onset in the first year of life. There were only 12
mutation positive children with epileptic encephalopathies who presented after the
age of 12 months. The latest presentation ofDravet-B was 26 months. Though
uncommon the diagnosis ofDravet Syndrome must be considered even if there is
onset of epileptic or febrile seizures in the second year or early into the third year of
life.
Although the onset of the first seizure was in the first year in 94% of cases the
median age of genetic diagnosis was 4.5 years, 4 years after the median age of onset.
At first analysis this appears a significant delay when faced with an infantile epileptic
encephalopathy in which developmental problems emerge in the second year of life
and the first few years are characterised by a refractory epilepsy. The picture may not
be altogether bleak as there is emerging evidence from our data that a significant
proportion of cases are being diagnosed early.
There are several reasons for the diagnosis to be delayed. Febrile seizures are
common in infancy and even febrile status epilepticus is regarded as a common
general paediatric problem. It is usually only when the seizures change in nature or
there are repeated admissions to ICU that the diagnosis ofDravet Syndrome is
considered. The full syndrome does not emerge until well into the second or third
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year of life though there can be a strong suspicion much earlier in many cases. Most
febrile seizures and febrile status epilepticus present to general paediatricians and
ICU specialists who are unlikely to have detailed knowledge ofDravet Syndrome.
The prevention or amelioration of the epileptic encephalopathy should be the primary
goal in management ofDravet syndrome and it is now widely accepted that early
aggressive therapy may have the potential to do this (Chipaux et al 2008; Mullen &
Scheffer 2009). To date this has not been shown in prospective studies but is one of
the research themes underway in Glasgow. My own clinical experience is that
controlling epileptic seizures in individual patients may lead to cognitive
improvement as detailed in chapter 9. Inherent in the concept of an epileptic
encephalopathy is that controlling the seizures should improve or abolish the
encephalopathy. Early diagnosis is important to allow treatment before there has
been significant cognitive impairment.
Children referred before 18 months usually do not have a clinical diagnosis ofDravet
Syndrome but a suspicion of the diagnosis. The youngest case was 7 months at
genetic diagnosis and we have made a diagnosis in 9 more infants under a year of
age. What is encouraging is that the highest number of diagnoses is being made in
the second year of life (31). 20% of children are diagnosed before their second
birthday and 30% prior to their 3 rd birthday.
We have an ongoing project looking at age at clinical diagnosis in the pre-genomic
era in Glasgow. This work is incomplete but early results suggest that with good
knowledge of the syndrome it was possible to make a clinical diagnosis late in the
second year in Dravet-C cases but that the diagnosis was delayed significantly in
Dravet-B. The diagnoses were made by experienced paediatric neurologists working
in a tertiary centre.
It is important to offer MLPA to all cases with onset in the first year of life and who
are not old enough to have developed sufficient features diagnostic ofDravet
Syndrome if they are negative on sequencing. All cases detected on MLPA had
Dravet-C phenotypes with onset in the first year.
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If a detailed history of the semiology and evolution of the seizures is available
Dravet Syndrome is recognisable in adults with learning disability and epilepsy
(Jannsen et al 2006). We have made a genetic diagnosis ofDravet Syndrome in 13
adults. It would be nice to think this reflects increasing awareness of paediatric onset
epilepsy syndromes amongst adult neurologists however most of the adult referrals
come from two UK centres.
In a retrospective study Hattori et al. compared the characteristics of seizures in the
first year of life in 46 patients with Dravet Syndrome (38/46 SCN1A mutations) and
50 patients with febrile seizures (Hattori et al 2008). From their analysis they
proposed several factors which could predict a diagnosis ofDravet Syndrome. The
Dravet syndrome group were more likely to have >5 seizures in the first year, onset
<7months, hemiclonic seizures, focal seizures and seizures longer than ten minutes.
They proposed a scoring system based on these factors that general paediatricians
could use to decide whether to request SCN1A gene analysis. The referral form
developed in Glasgow contains all these clinical details and we are currently
analysing the data to see which elements best predict the presence of a mutation in
our large sample.
Making a genetic diagnosis early in a child with an infantile onset encephalopathy
may lead to appropriate treatment controlling the epileptic encephalopathy but it may
have many other benefits. In the short term better seizure control may prevent
episodes of status epilepticus and the morbidity and mortality associated with this
medical emergency. With better control of the seizures long term cognitive and
behavioural outcome may improve with benefits for the individual, family and wider
society. Infants with epileptic encephalopathies would normally be subject to
multiple invasive and costly biochemical, electrophysiological, metabolic and
imaging investigations. A genetic diagnosis has the potential to save the health
service significant amounts ofmoney. Having a definitive diagnosis is important for
many families. It provides them with an explanation for their child's problem and
may lessen any feelings of guilt. Families frequently report that having a diagnosis to
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put on forms makes it easier for them to access certain services. A genetic diagnosis
allows genetic counselling. Many families with a severely disabled child will decide
not to consider having more children unless they understand the recurrence risks. The
vast majority ofDravet syndrome cases are due to de novo mutations in the gene
however somatic and germline mosaicism has been reported (Depienne et al 2006;
Gennaro et al 2006; Morimoto et al 2006). There is therefore a very small recurrence
risk even if both parents do not appear to carry the mutation on standard testing. In a
few selected cases we have agreed to prenatal diagnostic testing. This included two
cases in which an older sibling had a severe epileptic encephalopathy and had died
due to status epilepticus. The benefits to patients and physicians of genetic testing, is
one of the areas of ongoing and future research that I will discuss in chapter 11.
There has been much recent debate about the importance of genetic testing in
epilepsy. Some authors have acknowledged the major advances that have taken place
in our understanding of the genetic mechanisms that underlie epilepsy but still do not
regard genetic testing as contributing significantly to patient care (Delgado-Escueta
& Bourgeois 2008). I would argue that SCN1A genetic analysis has now become
established as the first genetic diagnostic test in epilepsy that can directly influence
patient management.
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That the channelopathies have emerged in the last 15 years as an important class of
neurological disorder is not surprising given the critical role of ion channels in
electrical signalling throughout the central and peripheral nervous system and
muscle. In excess of 400 genes are known to encode ion channels, making up 1-2%
of the human genome (Venter et al, 2001). The protein products of these genes, the
channel subunits, can combine in a variety of different combinations to produce
channels with distinct functions. Ion channels may be widely distributed or only
expressed in certain tissues. Alternative splicing of channel genes can lead to a
further variation in channel subtypes (Gargus, 2003). This enormous potential
diversity of ion channels helps explain the number and variety ofneurological
channelopathies and the distinct nature of conditions caused by mutations in the
same gene.
The phenotypic description of these disorders has led to genetic characterisation
which in turn has allowed further phenotypic analysis of the variability and
boundaries of individual syndromes. The clinician has a key role in these advances in
knowledge. The discovery that common neurological disorders such as the
epilepsies are largely a family of ion channelopathies has led to major advances in
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our understanding of the neurobiology of disease and the hope that improved more
targeted therapies can be developed. Although the major discoveries in the epilepsies
have been in monogenic disorders it is likely that ion channel variation will be a
major risk factor in common epilepsies with complex inheritance (Heron et al
2007b). Similarly the commonest neurological disorder, migraine, may be caused in
a significant proportion of patients by ion channel variation.
11.1 Epilepsy andmovement disorders
The studies of individuals and families with episodic ataxias type 1 and 2 (EA1 and
EA2) with epilepsy have broadened the phenotypic spectrum of these disorders and
provided insights into the relationships between epilepsy and movement disorders.
We have shown that the epilepsy and the movement disorder cannot be separated at
the molecular level and that the clinical distinction is likely to be influenced by the
following factors:
• The regional expression of the mutant ion channels.
• The neuronal network involved
• The nature / functional consequences of a specific mutation
• The stage in development the mutant ion channel is expressed
The same is true of the other features in these disorders including myokymia and
neuromyotonia in EA1 and migraine in EA2.
These findings suggest that other disorders in which epilepsy and movement
disorders are associated may also be caused by ion channel dysfunction. I have
studied a large Scottish family with benign familial infantile convulsions (BFIC) and
paroxysmal dyskinesia in collaboration with John Mulley in Adelaide (Figure 11.1).
This family links to the pericentromeric region of chromosome 16 (Figure 11.2). As
yet despite sequencing many candidate genes we have not found a mutation that
segregates with the disease. This syndrome in which benign epileptic seizures, which
usually remit in infancy, are followed by a paroxysmal kinesigenic dyskinesia in late
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childhood or teenage years is a strong candidate for an ion channel disorder
(Rochette et al. 2008).
The differential diagnosis or what has been termed the "Border-land ofEpilepsy" by
Gowers in 1907 and more recently by Crompton & Berkovic is an area of great
complexity and diagnostic challenges for the clinician (Gowers 1907; Stephenson &
Zuberi 2005; Crompton & Berkovic 2008). Molecular genetic studies allied to
detailed clinical descriptions are revealing that many of these borderland paroxysmal
disorders share an underlying pathophysiology in ion channel dysfunction.
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Figure 11.1 Benign familial infantile convulsions and paroxysmal dyskinesia
in a Scottish family
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Figure 11.2. Scottish family with benign familial infantile convulsions and
paroxysmal dyskinesia and other reports with linkage to pericentromeric





















































11.2 Ion channel associated proteins
Phenotypes of paroxysmal disorders resembling or identical to ion channelopathy
phenotypes may be caused by mutations in genes encoding structurally or
physiologically related proteins which influence channel function rather than in an
ion channel itself. This may be the case in BFIC and dyskinesia.
Ion channel subunits interact with a variety of proteins in the cell membrane. Kvl.l
channel function may be affected by mutations in the leucine-rich glioma
inactivation gene (LGI1) producing the phenotype of autosomal dominant partial
epilepsy with auditory features (Schulte et al 2006). Congenital myasthenias are
caused by presynaptic, synaptic and postsynaptic genetic defects in neuromuscular
transmission. A variety ofmutations have been described in different acetylcholine
receptor subunits causing congenital myasthenia (Table 1.1). The receptor associated
protein of the synapse (Rapsyn) is important in localising and maintaining the
acetylcholine receptor in the post synaptic cell membrane. Mutations of the Rapsyn
gene produce acetylcholine receptor deficiency and therefore a congenital
myasthenia responsive to pyridostigmine (Ohno et al 2002).
Hyeperkplexia or startle disease is a rare disorder associated with mutations in the al
or rarely the P2 subunit of the glycine receptor (Table 1.1). This disorder may present
in a dominant fashion in large families but is more commonly sporadic due to
compound heterozygousity. In this condition individuals have an excessive startle
response due to failure of the inhibitory functions of glycine in the brainstem and
spinal cord. Infants may have hypertonia with attacks of apnoea and sudden deaths
have been reported. It can respond to treatment with clonazepam. We have recently
participated in a study which has been the first to report a glycine transporter
mutation in a new form of hyperekplexia (Rees et al 2006). This is the first human
neurological disease caused by mutations in a transporter for a neurotransmitter. We
have identified two individuals with this disorder. Mutations in the SLC6A5 gene
encoding the glycine transporter (GlyT2) were detected in both these individuals by
Mark Rees and colleagues in Swansea. In one case there is a dominantly inherited
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mutation and the other case is homozygous for the nonsense mutation C1315T which
results in a truncated protein R439X (Figure 11.3). This child has unrelated parents.
GlyT2 related hyperekplexia is characterised by severe life threatening attacks of
apnoea in early infancy but with time, in the dominantly inherited cases, the tendency
to startle disappears and they can come offmedication. Our dominant case now plays
competitive rugby. In our homozygous case the tendency to startle has persisted and
she has remained on a small dose of clonazepam. The remarkable feature about this
individual, which is not noted in other genetic forms of hyperekplexia, is that she has
a learning disability. This is as yet unreported but developmental delay is a feature of
the other two cases worldwide with homozygous mutations in the glycine transporter
gene (Mark Rees personal communication). This suggests that this gene may be
important more widely in cognitive processes.
11.3 Cognitive impairment & behaviour problems associated
with channelopathies
The study of families with ADNFLE revealed frequent behavioural psychiatric
problems, a finding confirmed in other publications. The phenotype of the ion
channelopathies is commonly characterised by a paroxysmal disorder however there
is increasing evidence of chronic symptoms related to channel dysfunction. These
may be the relatively subtle features seen in the ADNFLE families or may be the
severe encephalopathy seen in infants with Dravet syndrome. The subtle memory
deficits reported in families with the potassium channelopathy EA1 deserve further
investigation especially as it is known that Kvl.l potassium antibody related limbic
encephalitis is associated with severe acquired memory impairment.
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Figure 11.3 Molecular evidence for SLC6A5 homozygous mutation in child
with hyperekplexia (Courtesy of Professor Mark Rees).
Molecular evidence for SLC6A5 R439X
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11.4 Genetic diagnosis in SCN1A related infantile epileptic
encephalopathies
The severe encephalopathy associated with Dravet syndrome is devastating for the
infant and their family. The prospect of early aggressive therapy offers some hope to
families and it will be important that this is followed up with prospective studies. We
are currently undertaking such studies in the large cohort of children referred to our
genetic service for which we have ethical approval for long term follow up. We are
looking at measures of cognition, behaviour and quality of life.
Genetic diagnosis is aiding clinicians in making an early diagnosis of SCN1A related
encephalopathies but it will be important to know whether physicians and families
regard the genetic diagnosis as helpful and whether genetics causes management to
change. We have ongoing studies looking at physician and parental attitudes to
genetic testing.
We have had DNA from a large number of children with infantile epilepsy, most
who do not have Dravet syndrome, and who do not have mutations in the SCN1A
gene. With appropriate consent we are able to look at other potential epilepsy genes
in this group. In collaboration with Professor Mark Rees in Swansea we are looking
at GABA receptor and transporter genes in this cohort.
A new gene with a phenotype that has some similarities to Dravet syndrome is the
protocadherin 19 gene. This was first described in families in which there was
epilepsy in females with mental retardation (EFMR) but more recently has been
found in a significant proportion of sporadic females resembling Dravet syndrome
(Dibbens et al 2008; Depienne et al 2009). We are planning to set up a service to
sequence this gene in selected SCN1A negative cases.
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11.5 Therapy for ion channel disorders
Many of the medications developed for the treatment of ion channel disorders such
as epilepsy in the pre genomic era have modes of action that influence ion channel
function. For example the anti-epileptic medication carbamazepine blocks voltage
gated sodium channels and can be used to treat a variety of epilepsies as well as the
neuromyotonia and paroxysmal ataxia in the potassium channelopathy EA1.
Ion channel pharmacology is an important area of research in CNS and peripheral
nerve drug development. Ion channels are the targets ofmany therapeutic
compounds whether they be for epilepsy, muscle disease, anaesthesia or pain relief.
The recognition that a rare inherited disorder of pain transmission, paroxysmal
extreme pain disorder (PEPD), is associated with gain of function mutations in the
sodium channel gene SCN9A has providing an important clue to the underlying
cause of pain syndromes (Fertleman et al 2009).
Genotype phenotype studies can suggest that a particular medication may be helpful
in a particular syndrome such as stiripentol in Dravet syndrome. This can then be
studied in double blind placebo controlled studies. Knowledge of the mode of action
of a drug linked to knowledge of the genetic defect and its functional consequences
may help to explain why a particular medication is helpful and promote development
of allied compounds. The knowledge that stiripentol enhances central GABA
transmission and that Dravet syndrome can now be conceptualised as a GABA
interneuronopathy may explain the effectiveness of this medication in this particular
syndrome. In chapter 7 I discussed the development of retigabine a medication which
specifically enhances the function of the M channel which is made of subunits that
are mutated in benign familial neonatal seizures. The new field of
pharmacogenomics will seek to develop medications tailored to an individual's
genotype with the hope that more targeted therapy will be more effective and have
fewer side effects.
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Gene therapy is not an immediate prospect for the neurological channelopathies.
Techniques such as exon skipping or upregulation of associated non mutant proteins
are under trial in genetic neuromuscular disorders such as Duchenne muscular
dystrophy however CNS disorders will present even greater challenges (Muir &
Chamberlain 2009).
Ten years ago I wrote an essay with the title "Ion Channels & Epilepsy; an exciting
future". In the field of the neurological channelopathies that future has arrived.
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Appendix 1. SCN1A referral form.
SCN1A mutation screening for infantile onset epilepsies
This is a joint clinical epileptology and molecular genetic service providing sequencing of all 26 exons of SCN1A and MLPA
(looking for large scale rearrangements) in selected sequencing negative cases. The test is performed within a National Health
Service Clinical Pathology Accredited (CPA) Lab and reporting times conform to national standards.
Testing is undertaken when a completed referral form accompanies the DNA/blood sample. The clinician managing the
individual's epilepsy may be best placed to complete the form. Completion of the form allows us to prioritise samples, this is
necessary for quality control purposes, audit and is essential for the provision of a joint clinical and molecular genetic service.
The likelihood of the laboratory identifying a mutation is dependent upon the phenotype of the affected individual. In the first
18 months of the service the overall mutation detection rate has been approximately 30% and in classical SMEI / Dravet
Syndrome cases between 80-90%.
Prenatal testing is not offered routinely. Cases can be discussed on an individual basis.
Referring Clinician Name & Institution:
(Please circle one ofthe following)
Child Neurologist Adult Neurologist General Paediatrician
Other Epilepsy Specialist (specify) Clinical Geneticist
Affected Individuals Name and Date of Birth:
Is the test for: Affected individual or carrier status? (Please indicate name and mutation of affected
relative)
Age at first epileptic / febrile seizure Details:
Any factors precipitating first seizure? Details:
Prolonged febrile seizures YES / NO Age ofonset:
Hemi-clonic or focal febrile seizures YES / NO Age ofonset:
Hemi-clonic or focal afebrile seizures YES / NO Age ofonset:
Did different focal seizures affect the opposite
side
YES / NO Details:
Myoclonic seizures YES / NO Age ofonset:
Generalised tonic-clonic / clonic seizure YES / NO Age ofonset:
Focal seizures with impairment of awareness YES / NO Age ofonset:
Atypical absences YES / NO Age ofonset:
Status epilepticus YES / NO Details:
225
Obtundation status YES / NO Details:
Has there been a prolonged seizure free period? YES / NO Ifyes, how long for?
Epileptic encephalopathy YES / NO Details:
Any other comments on seizure types: Details:
DEVELOPMENT:
YES (details) NO
Normal prior to epilepsy onset
Cognitive decline following epilepsy onset
Acquired autistic features
Behaviour problems
Acquired motor / movement disorder? (Please circle one ofthefollowing) hypotonia, ataxia, spasticity,
dyskinesia.
Is the movement disorder static or paroxysmal? Details:
Current developmental status: (please circle one ofthefollowing)
Normal Mild Moderate Severe Profound Learning disability
Age at which development noted to be abnormal
Continued development regression or plateau at a certain age?
EEG FEATURES: (Please provide details)
Please state date of EEG & abnormalities
Normal interictal EEG
Generalised spike & wave
Photosensitivity (any EEG with date)
Focal / multifocal EEG abnormalities




Have any medications increased seizure frequency?
Any medications reduced seizure frequency?
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FAMILY HISTORY: (Please provide details/pedigree of family history of febrile seizures or epilepsy in space provided)
SYNDROMIC DIAGNOSIS: (Please circle one ofthe following)
■ Severe myoclonic epilepsy in infancy / Dravets Syndrome
■ Borderline severe myoclonic epilepsy (SMEB)
■ Intractable childhood epilepsy with generalised tonic clonic seizures
■ Specific epilepsy syndrome within a family with generalised epilepsy and febrile seizures
plus (GEFS+). (Please draw pedigree and state syndromes in space above)
■ Other Syndrome- please specify
■ Unclassified epilepsy
COMMENTS: (Please provide any other relevant details in space provided below)
INVOICE DETAILS: (Samples from outside Scotland should provide details of billing address below)
* Clinical queries can be directed to Dr Sameer Zuberi, Consultant Paediatric Neurologist
(sameer.zuberi@ggc.scot.nhs.uk)
* Queries relating to technical aspects of the mutation analysis can be directed to Rachael Birch
(rachael.birch@ggc.scot.nhs.uk).
DNA or whole blood (2-5ml in an EDTA tube) should be forwarded to Rachael Birch, DNA Lab,
Duncan Guthrie Institute ofMedical Genetics, Royal Hospital for Sick Children, Yorkhill,
Glasgow, United Kingdom, G3 8SJ. Tubes must be labelled with name and date of birth.
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BDU 9ZX cc: DNA Laboratory,
Borchester
SURNAME Smith PEDIGREE NO.
FORENAME John LAB NUMBER D1111111
DATE OF BIRTH 10/11/2004 TYPE OF SPECIMEN DNA
HOSPITAL NO. 33333333 DATE RECEIVED 07/08/2007
NHSNO. 4444444 DATE ACTIVATED 09/09/2007
Reason for Referral: Affected by Severe Myoclonic Epilepsy of Infancy (SMEI)
Test Required : Multiplex Ligation-dependant Probe Amplification (MLPA) was undertakei
detect deletions or duplications of the SCN1A gene.
MOLECULAR GENETICANALYSIS REPORT
RESULT:
John Smith Deletion of exons 1-16 of the SCN1A gene
CONCLUSION:
Previous genetic testing performed on this patient involved direct sequencing of the SCNl^
gene. This test did not identify a pathogenic mutation.
Due to the reported phenotype we went on to carry out MLPA analysis of the SCN1A gene.
This test has identified a large deletion that includes exons 1 to 16 of the SCN1A gene.
Patients with SMEI and associated infantile onset epilepsies may have large scale re¬
arrangements of the SCN1A gene (Mulley et al 2006). The mutation identified is very likeb
be associated with the epilepsy phenotype in this patient.
The P137 probe mix contains probes for 25 of the 26 exons of the SCN1A gene. The NM_006920.2 sequence was used to design the MLPA kit.
References:
Mulley JC et al. (2006). A new molecular mechanism for severe myoclonic epilepsy of infancy: exonic
deletions in SCN1A. Neurology. 2006 Sep 26;67(6): 1094-5.
http://www.mlpa.com
Molecular Geneticist: Rachael Birch Checked by:
Consultant Paediatric Neurologist: Dr Sameer Zuberi Date reported: 10/10/2007
(SltsSi A CPA (UK) Ltd fully accredited laboratory
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